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ABSTRACT 
 
The objective of this work was to develop adenovirus-vectored prototype vaccines 
against two pathogens, African Swine Fever Virus (ASFV) and Bovine Viral Diarrhea 
Virus (BVDV), which cause disease in two major livestock species, swine and cattle 
respectively.  
The African Swine Fever Virus is a transboundary animal pathogen that causes a 
lethal hemorrhagic fever in domestic pigs. Attempts to develop a vaccine for ASFV have 
failed thus far. This manuscript describes the use of recombinant adenovirus to deliver 
two unique formulations of ASFV antigens in swine (in two separate in-vivo studies) and 
the subsequent evaluation of the antigen-specific antibody and cellular responses 
induced. The robust antigen-specific immune responses observed in both studies are 
promising and their protective potential will be evaluated in future efficacy studies 
The Bovine Viral Diarrhea Virus is a globally prevalent pathogen that can cause 
severe diarrhea, respiratory disease, abortions and sometimes death in calves. Killed and 
modified live vaccines (MLV) for BVDV have been in use since the 1960s but are not 
effective due to lack of cross-protection and retention of immunosuppressive 
characteristics. This thesis also describes the use of the recombinant adenovirus vector to 
deliver a cocktail of multiple mosaic BVDV antigens in calves followed by the 
evaluation of protection conferred upon challenge. The prototype vaccine was more 
immunogenic and cross-protective (based on neutralizing antibodies) than a commercial 
MLV BVDV vaccine. Regarding protective efficacy, all calves immunized with 
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prototype vaccine cleared the virus within a week post-challenge, whereas one calf that 
received the MLV vaccine still remained viremic. Future efficacy studies with diverse 
BVDV strains are required to validate the cross-protective potential of this prototype 
vaccine.  
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CHAPTER I  
INTRODUCTION  
 
Traditional approaches for developing vaccines, such as inactivated or live-attenuated 
vaccines have proved successful against several veterinary viral pathogens. Examples 
would be the attenuated rinderpest virus vaccine (Plowright vaccine) which is 
responsible for the global eradication of rinderpest or the recently licensed inactivated 
porcine circovirus Type 2 (PCV2) vaccine for prevention of postweaning-multisystemic 
wasting syndrome in pigs [1]. However, these approaches have certain limitations. The 
biggest concern with live attenuated vaccines is safety. These vaccines pose a risk of 
introduction of carrier states due to incomplete viral clearance and the possibility of 
reversion to virulent strain. Two examples of use of live-attenuated vaccines in the past 
serve as reminders to proceed with caution when trying to deploy these vaccines in the 
field. The first example is of the use of live attenuated North-American strain of Porcine 
Respiratory and Reproductive Syndrome Virus (PRRSV) to vaccinate against the 
European strain prevalent in Denmark in 1996. The vaccine strain reverted to virulence 
and ultimately led to the introduction of a new strain in Denmark [1, 2]. Another 
example is the use of attenuated African Swine Fever Virus (ASFV) strain in Portugal in 
1970 which resulted in severe immune-mediated reactions in the vaccinated pigs. 
Inactivated vaccines, though safer, are generally not as immunogenic and require strong 
adjuvants. In addition, since they are not actively replicating, the viral antigens are not 
processed by the MHC-I presentation pathway (cross-presentation may occur) and hence 
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these vaccines are not efficient at priming CD8+ T-cells. This lack of induction of 
cytotoxic T-lymphocytes (CTLs) results in inefficient clearance of virus-infected cells. 
Furthermore, the use of strong adjuvants poses a greater risk of inducing auto-immune or 
allergic disorders and inoculation-site sarcomas [3]. 
An alternative approach for developing vaccines is use of live viral vectors. 
Recent advances in the fields of viral molecular biology and genetics have enabled the 
development of recombinant viral vectors for vaccine and immunotherapeutic 
applications. Use of recombinant viral vectors for in-vivo delivery of antigens is 
relatively safer than attenuated virus vaccines because the viral particles produced are 
replication deficient/incompetent and hence do not pose a threat to the host. This 
approach is better than using recombinant proteins because live vectored vaccines allow 
for intracellular expression of the antigen in the cytoplasm and thus making it amenable 
for MHC-I presentation and subsequent priming of CD8+ T-lymphocytes. Antigen 
released from the infected cells is also taken up via the endocytic pathway for MHC-II 
presentation to prime CD4+ T-lymphocytes. Another advantage of vectored vaccines is 
that the viral vector backbone is capable of stimulating innate immune responses due to 
the presence of Pathogen Associated Molecular Patterns (PAMPS). One limitation of 
using this approach, however, is the requirement for identification of protective vaccine 
candidate antigen(s) such that the immune response generated against the antigen(s) is 
sufficient for conferring protection against the pathogen. 
The major focus of this work was to develop adenovirus-vectored prototype 
vaccines for the African Swine Fever Virus. This virus is a large double-stranded DNA 
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virus with a 170-190 kb long genome that encodes for >150 proteins. The aim was to use 
adenovirus as a delivery vector to evaluate the immunogenicity of several ASFV 
antigens in swine with an overarching goal of identifying promising candidates for 
inclusion in a multi-antigen prototype vaccine. We selected the replication deficient 
human adenovirus as a delivery vector due to several reasons such as its safety track 
record, large capacity for transgenes, high transgene expression, replicates at high titers in 
complementing cell lines and thus production is scalable and reproducible. A single dose of 
an adenovirus-vectored vaccine induces robust immune responses in neonates [4-9]. 
Importantly, adenovirus-vectored vaccines can be administered via multiple routes such as 
intradermal and intranasal for induction of systemic and mucosal immunity [7, 10-12]. More 
importantly, an adenovirus vector induces both antibody as well as T-cell responses and it has 
been shown that a single dose immunization with an adenovirus-vectored vaccine induces 
stronger CTL responses than recombinant vaccinia virus vector, plasmid DNA, or a 
combination of these two [13].  In addition, an adenovirus vector induce both innate and 
adaptive immune responses in mammalian hosts, in part, by dendritic cell (DC) modulation 
through Toll-Like Receptor (TLR)-dependent and -independent pathways [4-6]. 
Furthermore, adenovirus transduces Langerhans cells efficiently and immunization of 
neonates at birth with a single dose of an adenovirus-vectored vaccine induces robust 
immune responses [11, 14].  Relevant to this project, it is important to note that adenovirus 
vectors have been used successfully in swine immunization studies and have been shown to 
be safe and efficacious [15-19].  
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Chapters II and III of this dissertation describe the results of two separate in-vivo 
studies where the immunogenicity and safety of two cocktails of recombinant adenoviruses 
expressing rationally selected ASFV antigens were evaluated in swine. The first study 
evaluated a cocktail of well characterized and previously evaluated ASFV antigens at two 
doses and formulated in two novel adjuvants. The second study evaluated a cocktail of novel 
ASFV antigens that haven’t been previously evaluated for their immunogenic potential.  
Past efforts on ASFV vaccine development, justification for using this delivery platform 
along with rationale for selection of the antigens have been elaborated upon in the 
introductions of these two chapters. In addition to these efforts of developing prototype 
vaccines for ASFV, the recombinant adenovirus delivery platform was also used to evaluate 
the protective efficacy of a multi-antigen cross-protective Bovine Viral Diarrhea Virus 
(BVDV) prototype vaccine in calves. A similar immunogen-adjuvant formulation of 
recombinant adenoviruses expressing mosaic BVDV antigens was inoculated into calves 
which were then subsequently challenged by a BVDV type 2a strain. The results of this 
study are described in Chapter IV. A brief background on the virus, its pathogenesis, 
problems associated with the currently available vaccines and the rationale for developing 
this prototype vaccine are discussed in the introduction of the chapter.  
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CHAPTER II                                                                                                               
INDUCTION OF ROBUST IMMUNE RESPONSES IN SWINE USING A 
COCKTAIL OF ADENOVIRUS-VECTORED AFRICAN SWINE FEVER VIRUS 
ANTIGENS* 
2.1. Overview 
The African Swine Fever Virus (ASFV) causes a fatal hemorrhagic disease in domestic 
swine and, at present, no treatment or vaccine is available.  Natural and gene-deleted, 
live attenuated strains protect against closely related virulent strains, however, they are 
yet to be deployed and evaluated in the field to rule out chronic persistence and potential 
for reversion to virulence. Previous studies suggest that antibodies play a role in 
protection, but induction of cytotoxic T-lymphocytes (CTLs) could be the key to 
complete protection.  Hence, generation of an efficacious subunit vaccine depends on 
identification of CTL targets along with a suitable delivery method that will elicit 
effector CTLs capable of eliminating ASFV-infected host cells and confer long-term 
protection.  To this end, we evaluated the safety and immunogenicity of an adenovirus-
vectored ASFV multi-antigen cocktail formulated in two different adjuvants and at two 
immunizing doses in swine.  Immunization with the cocktail rapidly induced 
unprecedented ASFV antigen-specific antibody and cellular immune responses against 
                                                 
* Reprinted with permission from “Lokhandwala S, Waghela SD, Bray J, Martin CL, 
Sangewar N, Charendoff C, et al. Induction of Robust Immune Responses in Swine by 
Using a Cocktail of Adenovirus-Vectored African Swine Fever Virus Antigens. Clinical 
and Vaccine Immunology. 2016;23(11):888-900. doi: 10.1128/cvi.00395-16.”  
Copyright © American Society for Microbiology. 
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all the antigens.  The robust antibody responses underwent rapid isotype-switching 
within one-week post-priming, steadily increased over a two-month period and 
underwent rapid recall upon boost. Importantly, the primed antibodies strongly 
recognized the parental ASFV (Georgia 2007/1) by IFA and western blot. Significant 
antigen-specific IFN-γ+ responses were detected post-priming and post-boosting.  
Furthermore, this study is the first to demonstrate induction of ASFV antigen-specific 
CTL responses in commercial swine using Ad-ASFV multi-antigens. The relevance of 
the induced immune responses in regards to protection need to be evaluated in a 
challenge study. 
2.2. Introduction 
African Swine Fever (ASF) is a highly contagious and fatal hemorrhagic swine disease.  
It has case morbidity and mortality rates that approach 100% [20].  Swine that recover 
become carriers and shed the virus for up to 70 days [21].  There is no treatment or 
vaccine available, and the only control strategy in case of an outbreak is quarantine, and 
removal of infected and in-contact animals.  The ASF causes economic losses worldwide 
and severely affects the pork industry in sub-Saharan Africa where it is endemic [22]. 
The pathogen, African Swine Fever Virus (ASFV), is a double-stranded DNA 
enveloped icosahedral arbovirus belonging to the genus Asfivirus and the only member 
in the family Asfarviridae [23].  ASFV has a 170-190 kb non-segmented genome 
containing 150-167 ORFs [24, 25].  The ASFV has a natural sylvatic transmission cycle 
between Ornithodoros tick species and wild suids such as warthogs [22].  Infections in 
wild suids are asymptomatic and persistent, leading to a carrier state and transmission to 
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domestic pigs, which hinders eradication. Although an effective ASFV vaccine has not 
yet been developed, the fact that swine exposed to less virulent isolates (naturally or 
experimentally attenuated) are protected when challenged with homologous or closely 
related virulent isolates, suggests that vaccine development is possible [26-28].  
Published data suggests that antibodies and T-cells play critical roles in virus control 
[28-35]. ASFV-infected convalescent swine serum can neutralize the infectivity of 
homologous and some heterologous strains in vitro and in vivo, possibly by inhibiting 
virus attachment and internalization [35-38].  Generally, anti-ASFV antibodies are 
detectable from about 6 days post-infection, and if the animal survives, antibodies may 
persist for long periods.  However, despite the presence of antibodies, virus 
neutralization may not occur.  Thus, the specific role of antibodies in ASFV protection is 
not yet fully understood [39].  The importance of cytotoxic T-lymphocytes (CTLs) in 
protection against ASFV has been demonstrated in a number of studies.  Importantly, in 
vivo depletion of CD8+ T-cells decreases protection against ASFV in swine and in vitro 
studies indicate that there is preferential proliferation of CD8+ T-cells in the presence of 
live virus, whereas both CD4+ and CD8+ T-cells are stimulated by UV-inactivated virus 
[33, 40].  In addition, ASFV-specific CTL activity is detected in swine infected with 
non-lethal ASFV isolates [28, 29, 31, 32].  The requirement for CTLs in protection is 
further supported by the observation that adjuvant-formulated killed ASFV and 
recombinant vaccine candidate antigens that induce high antibody responses do not 
confer solid protection, and these outcomes strongly suggest that MHC class I 
presentation of ASFV antigens is critical [34, 41-44].  In addition, it has been observed 
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that swine that generate high antibody titers, but low cellular responses following 
immunization with a live, attenuated virus, develop chronic disease [45]. 
Although live attenuated ASFV can protect swine against the disease, it is not an 
ideal vaccine due to the potential risk of vaccine virus persistence and reversion to 
virulence.  Additionally, a live, naturally-attenuated ASFV vaccine used in Portugal in 
the 1960s resulted in severe immune-mediated post-vaccination reactions in immunized 
animals, precluding any further use during outbreaks [46].  Subunit vaccines based on 
some of the most extensively studied ASFV antigens such as p32, p54, and p72 envelope 
protein, have shown some promise.  These antigens, among others, have been tested as 
vaccine candidates either as baculovirus-expressed recombinant proteins or via DNA 
plasmid delivery [34, 41-44].  Delayed onset of viremia, delayed mortality and partial 
protection have been observed in most of these studies, which suggest that these antigens 
do play a role in protection but are not capable of conferring complete protection when 
used singly or in combination.  Thus, it is envisaged that development of an efficacious 
vaccine requires empirical identification of multiple ASFV antigens formulated in a 
suitable delivery system that can successfully induce robust immunity.  
Given that one or a combination of a few subunit antigens have not been able to 
confer complete protection so far, we set out to test the ability of a live-vectored ASFV 
multi-antigen cocktail to elicit strong CTL, IFN-γ-secreting T-cell, and B-cell responses.  
We selected replication-deficient human adenovirus (Ad5) vector as the antigen delivery 
platform for several reasons such as safety, high transgene expression and scalability [4-
7, 9].  Additionally, adenovirus-vectored vaccines have been shown to induce stronger 
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CTL responses than vaccinia virus, plasmid DNA or a combination of these two [13].  
To test our approach, we used p32, p54, and p72 antigens since they are well 
characterized.  Furthermore, antigens p32 and p72 have been previously identified as 
CTL targets [29, 31].  We also included polyprotein pp62,  which is a major component 
of the core shell, essential for viral core development and is very strongly recognized by 
ASFV-specific convalescent serum [47].  We tested this multi-antigen (4-way) cocktail 
in a prime-boost regimen using two different adjuvant formulations and at two different 
immunizing doses.   
2.3. Material and Methods 
2.3.1. Generation of plasmid constructs encoding ASFV antigens 
The ASFV p32, p54, pp62 polyprotein (pp62), and p72 amino acid sequences based on 
the epidemiologically relevant Georgia 2007/1 isolate (GenBank accession FR682468) 
were modified to add, in-frame, a FLAG- and HA-tag at the N- and C-termini, 
respectively. This allowed for the use of one primer pair to move the expression 
cassettes of all antigens across multiple expression vectors, in addition to using the tags 
for tracking protein expression and affinity purification of recombinant proteins.  The 
resultant amino acid sequences of the ASFV antigens were used to design synthetic 
genes codon-optimized for protein expression in the swine host. Codon optimization, 
gene synthesis, cloning into pUC57, and gene sequence validation was outsourced 
(GenScript). Each gene was then subcloned into pcDNA™3.3-TOPO® TA, 
pAd/CMV/V5-DEST™Gateway®, and pFastBac™ HBM TOPO vectors (Invitrogen) to 
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generate DNA plasmid constructs for protein expression in mammalian cells, generation 
of recombinant adenoviruses, and recombinant baculoviruses, respectively, using 
manufacturer’s protocols. The constructs generated were validated by DNA sequencing. 
2.3.2. Generation of virus constructs encoding ASFV antigens 
The pAd constructs mentioned above were used to generate recombinant replication-
incompetent adenoviruses using the ViraPower Adenoviral Expression System 
(Invitrogen). Following validation of protein expression by immunocytometric analysis, 
the recombinant adenoviruses were scaled up to generate virus for immunizations.  Virus 
titers (infectious focus units, IFU) were determined using the QuickTiter™ Adenovirus 
Titer Immunoassay Kit (Cell Biolabs, VPK-109) with a minor modification.  We used 
purified rabbit anti-adenovirus polyclonal IgGs (1:500 dilution) (made in-house by 
immunizing rabbits with heat killed Ad-Luciferase) as the primary antibody, followed by 
an alkaline-phosphatase-conjugated  anti-Rabbit IgG (1:1,000) (Jackson 
ImmunoResearch, Cat #711-055-152) as the secondary antibody and Fast Red TR–
Naphthol AS-MX as the substrate (Sigma, F4523). A recombinant adenovirus 
expressing luciferase (Ad-Luc) was similarly scaled up and titrated to serve as the 
negative control immunogen. To generate recombinant baculoviruses, the pFastBac 
constructs were used to generate Bacmids which were subsequently transfected into Sf-9 
cells.  One clone of each baculovirus was scaled up, titered and then used to infect High-
Five cells (Invitrogen) to generate FLAG-tagged recombinant proteins which were 
affinity purified with anti-FLAG M2 affinity gel (Sigma, A2220).  Recombinant pp62 
was generated using the HEK 293 Freestyle Expression system (Invitrogen).  
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2.3.3. Evaluation of protein expression  
Protein expression by the plasmid constructs, and by the recombinant viruses encoding 
the ASFV antigens was validated by immunocytometric analysis as previously described 
[48].  Briefly, HEK-293A cell monolayers transfected with the plasmid constructs or 
infected with the recombinant adenoviruses, were probed with mouse anti-FLAG M2–
alkaline phosphatase conjugate (Sigma, St. Louis, MO) diluted 1:1,000 in Blocking 
buffer (PBS with 5% fetal bovine serum).   Duplicate transfected or infected HEK-293A 
cell monolayers were first incubated with a gamma-irradiated convalescent swine serum 
(1:500) (Several ASFV isolates were used to produce the convalescent sera from a donor 
pig that was sequentially infected with a series of tissue culture adapted and wild-type 
viruses from p72 genotypes I (DR11, Haiti 81, Lisbon 60, Malawi 83and UG-61], VIII 
and X. The serum was a kind gift from E. J. Kramer, Plum Island Animal Disease 
Center) and then probed with a 1:1,000 dilution of alkaline phosphatase-conjugated goat 
anti-porcine IgG (Southern Biotech, Cat# 6050-04).  The alkaline phosphatase activity 
was then detected using Fast Red TR–Naphthol AS-MX substrate (Sigma, F4523). Mock 
transfected/infected cells served as negative controls. Protein expression by the 
generated recombinant baculoviruses was similarly evaluated by probing infected Sf-9 
cells. 
2.3.4. Immunization of swine   
Twenty weaned piglets (barrows; ~30lbs) were acquired and during the quarantine 
period, commercial vaccines against defined pathogens were administered to meet 
institutional requirements.  Three groups of piglets (n=5), were immunized with a 
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cocktail of the recombinant adenoviruses expressing ASFV antigens formulated in 
defined adjuvants (Table 1).  Sham-control piglets (n=5) were inoculated with an 
equivalent amount of the Ad-Luc virus (Table 1). The inoculum was administered 
intramuscularly in the neck region behind the ears.  Fourteen weeks post-priming, the 
animals were boosted with the cognate priming dose and adjuvant.  The pigs were 
terminated, one group a week starting at 8 weeks post-boost. 
Table 1: Swine Immunization Protocol 
Group No. of pigs Immunogen Dose/pig Adjuvant 
T1 5 Ad5-ASFV 4-way cocktail 4 X 1010 IFU* ENABLδ 
T2 5 Ad5-ASFV 4-way cocktail 4 X 1011 IFU** ENABL 
T3 5 Ad5-ASFV 4-way cocktail 4 X 1011 IFU** Zoetisϕ 
T4 5 Ad5-Luc 4 X 1011 IFU*** ENABL 
* ASFV 4-way cocktail: pool of 4 Ad5-ASFV constructs each at 1 x 1010 IFU (Infectious 
Focus Units) 
**   ASFV 4-way cocktail: pool of 4 Ad5-ASFV constructs each at 1 x 1011 IFU 
*** Ad5-Luc sham inoculated control  
δENABL adjuvant (Cat. # 7010106-C6) 
ϕExperimental adjuvant (proprietary formulation) 
 
 
2.3.5. ELISA 
Direct ELISA was used to evaluate antigen-specific antibody responses as previously 
described [48].  Briefly, microplates coated with 100 µl of 1μg/ml of affinity-purified 
antigen in Bicarbonate coating buffer were first incubated with 100 ul of sera (diluted at 
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1:100) in triplicates, followed by incubation with 100μl of Peroxidase-conjugated anti-
swine IgG (Jackson ImmunoResearch, Cat. #114-035-003) (1:5,000 dilution).  The 
plates were developed using Sure Blue Reserve TMB substrate (KPL, Cat.# 53-00-02) 
and the reaction stopped using 1 N Hydrochloric acid.  The optical density at 450 nm 
was then determined using a microplate reader. To determine antigen-specific IgM 
responses in sera from blood collected week 1 post-priming, HRP conjugated anti-swine 
IgM (1:10,000) (Bethyl Laboratories, A100-100P) was used as the secondary antibody.  
Antigen-specific IgG end point titers were determined for sera from blood collected 
week 1 post-boost by making a range of two-fold serum dilutions starting at 1: 1.6 X 104 
to 1: 1.6 X 107.  Similarly diluted pre-immunization sera served as cognate controls.  
The titer was then determined to be the dilution of the post-boost sera for which the 
mean of the OD was higher than the mean +3 times the standard deviation of the cognate 
pre-immunization sera. The significance of the difference in antigen-specific IgG titers 
among the groups was determined by ANOVA, followed by Tukey’s multiple-
comparison test, and a P value of ≤ 0.05 was considered significant. 
2.3.6. Indirect Fluorescence Antibody assay (IFA) 
Teflon-coated slide wells (Electron Microscopy Sciences, Cat. No. 63425-05) were pre-
treated by incubating with 300 μg/ml of rat-tail collagen (Corning, Cat. No. 354249) in 
D-PBS (Invitrogen 14190-144) for 1hr at 37°C, oven-drying for 30 mins and incubating 
overnight in a bio-safety cabinet (15 cm from UV light). Primary 
monocytes/macrophages were isolated from whole swine blood as previously described 
[49] and infected with ASFV (Georgia 2007/1) at 1 MOI for 1 hr.  at 37°C. 
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Approximately 4 x 105 infected cells and also mock-infected cells were then added to the 
wells of the pre-treated Teflon slides (25 μl/ well). The slides were incubated overnight 
at 37°C with 5% CO2, followed by fixing with a chilled (-20°C) solution containing 
acetone and methanol (1:1) for 10 min and stored at -70°C until required. To carry out 
the IFA, the slides were incubated with blocking solution (5% non-fat dry milk, 2% 
horse serum, 2% calf serum, 2% fetal calf serum and 5% BSA in D-PBS) for 30 min in a 
humidified chamber at 37°C. After blocking, the infected and mock-infected wells were 
incubated with a 1:20, 1:100 and 1:200 dilution of sera (week 1 post-boost) in blocking 
buffer for 1hr. at 37°C. ASF-specific convalescent serum (1:500) was used as a positive 
control and normal swine serum (GIBCO) was used as a negative control. Following 
three rinses with D-PBS, the wells were then incubated with FITC-conjugated goat anti-
swine sera (Kirkegaard and Perry Cat No. 02-14-02) for 45 minutes at 37°C. The wells 
were rinsed similarly again and mounted with Prolong Gold antifade reagent with DAPI 
(Invitrogen, Cat. No. PT389868). The results observed at 1:20 serum dilution are 
represented in Fig. 5A and the results of 1:200 serum dilutions are summarized in Table 
2. The IFAs were conducted at Plum Island Animal Disease Center. 
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Table 2: Summary of IFA Data  
  
T1: 
 Swine No. 
  
Reactivity 
  
T3: 
Swine No. 
  
Reactivity 
ASFV-infected 
Macrophage 
Mock-infected 
Macrophage 
ASFV-infected 
Macrophage 
Mock-infected 
Macrophage 
33 ++ - 31 +++ - 
35 +++ - 37 ++ - 
36 +++ - 93 ++++ Best - 
40 ++ - 94 +++ - 
42 ++ - 96 +++ - 
T2: 
Swine No. 
    T4:  
Swine No. 
    
34 +++ - 32 - - 
41 ++ - 38 - - 
43 ++++ - 39 - - 
46 +++ - 44 - - 
48 +++ - 45 - - 
Anti-ASFV 
convalesce
nt serum 
++++ - Normal 
serum  
-   - 
The reactivity of the serum from each animal was compared to the reactivity of the 
positive control serum i.e. ASFV-specific convalescent serum.  The number of + signs 
represents the intensity of the reaction, with ++++: as strong as positive control serum; 
and ++: weak but positive signal. 
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2.3.7. Western blot  
Swine sera from week 1 post-boost were blotted against cell lysates prepared from 
Georgia 2007/1 ASFV (Vero cells adapted)-infected Vero cells (ATCC CCL-81). 
Briefly, ASF-infected Vero cells exhibiting cytopathic effect (CPE) at 72 hr. post-
infection were harvested by centrifugation, lysed in M-PER Reagent (Thermo Scientific 
#78501), mixed 1:1 with 2X NuPAGE® LDS Sample Buffer, boiled, electrophoresed on 
a NuPAGE 4-12% Bis-Tris Gel for 35 minutes and transferred to 0.2um PVDF 
membranes (Invitrogen #LC2002). Following blocking in PBST containing 5% non-fat 
dry milk, membranes were transferred to the Protean II Slot-Blotter and incubated with 
sera diluted 1:50 in blocking buffer in individual wells. Following washes, the 
membranes were then removed from the blotting apparatus and incubated with Goat 
anti-swine-HRP (KPL #14-14-06) diluted 1:2,000 in blocking buffer for 1 hr. The blots 
were washed and then developed by exposure to DAB substrate (Sigma #D4293). 
ASFV-specific convalescent serum (1:10,000) was used as a positive control and normal 
swine serum was used as a negative control (1:200). A similar blot was carried out using 
mock-infected cell lysates to gauge background reactivity to host cell antigens. These 
western blots were performed at Plum Island Animal Disease Center. 
2.3.8. IFN-γ ELISPOT assays 
The frequencies of antigen-specific IFN-γ-secreting T-cells were determined by an 
enzyme-linked immunospot (ELISPOT) assay bi-weekly post-priming and weekly post-
boost. The assay was conducted in triplicate wells of MultiScreen-HA plates (Millipore) 
using the Mabtech kit (Cat. # 3130-2A), as per manufacturer’s instructions and as 
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described previously [48].  Briefly, 0.25 X 106 whole blood derived PBMCs or 
splenocytes were incubated with affinity purified antigens (2.5 μg/ml) in 100 μl per well 
of complete RPMI-1640 media. PHA mitogen (5 μg/ml) was used as a positive control 
and media alone served as a negative control.   The spots were quantified with an 
ELISPOT reader and AID software (AutoImmun Diagnostica V3.4, Strassberg, 
Germany). The results were presented as the mean number of antigen-specific IFN-γ 
spot-forming cells per 106 PBMCs after subtracting background media counts. The 
significance of the differences in IFN-γ+ PBMC responses between each vaccinated 
group (T1, T2, T3) and control group (T4) was analyzed by ANOVA, followed by 
Bonferroni's multiple-comparison test, and a P value of ≤0.05 was considered 
significant. 
2.3.9. CTL assays 
A standard chromium (51Cr) release assay was used to measure antigen-specific T-cell 
cytotoxicity as previously described [50]. 
2.3.9.1. Generation of effector cells 
PBMCs isolated from blood collected four weeks post-boost were resuspended in RPMI 
1640 media (Lonza) containing 45% Click’s Media (Irvine Scientific, Cat# 9195), 10% 
FBS, 1X β-Mercaptoethanol, 1X Glutamax, 50 μg/ml Gentamycin, 1X Pen/Strep 
(GIBCO) at a cell density of 4 X 106 /ml and distributed in aliquots of 1ml/well of a 24-
well culture plate.  The PBMCs were infected with each of the recombinant 
adenoviruses at a 1000 MOI for in-vitro stimulation of the T-cells.  After 10 days, the 
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cells were harvested and centrifuged on a Ficoll gradient to remove dead cells.  The live 
cells were then washed with PBS, resuspended in complete RPMI 1640 and counted to 
serve as effectors for the CTL assay.  
2.3.9.2. Generation of target cells 
Prior to immunization, skin biopsies were taken from each piglet using 4mm biopsy 
punches (American Screening Corp., Cat # 3785707).  Primary skin fibroblast cultures 
were established from these skin tissues as previously described [51]. Briefly, the skin 
tissues were cut into small pieces under sterile conditions and cultured in 12-well plates 
containing 1 ml DMEM supplemented with 10% FBS, 1X Glutamax, 50 μg/ml 
Gentamycin, 1X Pen/Strep (GIBCO).  When the fibroblasts reached confluency, they 
were passaged and frozen regularly till sufficient stocks were generated. Target cells 
were generated 24 hr.  prior to conducting the CTL assay by transfecting autologous 
fibroblasts with the pCDNA plasmid constructs expressing the ASFV antigens using 
Gene-In transfection reagent (MTI-Global Stem, GST-1000) as per manufacturer’s 
instructions. Transfection efficiencies of about 20-30% were achieved (pre-determined 
by immunocytometric analysis). On the day of conducting the assay, the cells were 
detached using Accutase, washed with DMEM containing 10% FBS, labelled with 100 
μCi per 106 cells of Na251CrO4 (Perkin Elmer) for 1hr. at 37°C, 5% CO2 washed three 
times and resuspended in complete RPMI 1640 for use as targets in the assay. 
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2.3.9.3. Chromium release assay 
The effectors and targets were added at effector: target ratios of 50:1 and 25:1 in 
duplicate wells of a 96-well round bottom microtiter plates in final volumes of 100 μl 
per well and incubated at 37°C, 5% CO2 for 6h. The plate was then centrifuged at 1000 
rpm for 4 min and supernatants harvested to measure chromium release in a Micro-beta 
counter (Perkin Elmer, 1450 LSC & Luminescence counter). Spontaneous release of the 
label was measured from supernatants of targets incubated without effectors and 
maximum release was measured from targets lysed with 5% Triton-X. Percent specific 
lysis was calculated as described previously [50]. Fibroblasts transfected with a construct 
expressing a chimera of VP1 and 3D polymerase antigens of the Foot and Mouth 
Disease Virus (FMDV) served as a negative control to assess background lytic activity.  
2.3.10. Statistical analysis 
All analyses were performed with GraphPad Prism Version 6.05 using a significance 
level of P<0.05. The antigen-specific IgG titers amongst the treatment groups were 
compared using One-way ANOVA followed by Tukey’s multiple comparison test. For 
all the IFN-γ ELISPOT assays, the mean IFN-γ response of treatment groups (T1-T3) 
was compared to the mean response of the sham treated control group (T4) using One-
Way ANOVA followed by Bonferroni’s multiple comparison test.  
2.3.11. Ethics statement 
All animal procedures were conducted in accordance with the Animal Use Protocol 
2012-59, reviewed and approved by the Texas A&M University Institutional Animal 
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Care and Use Committee (IACUC) (Permit 2009067) which adheres to the regulations, 
policies and guidelines outlined in the Animal Welfare Act (AWA), USDA Animal Care 
Resource Guide and the PHS Policy on Humane Care and Use of Laboratory Animals. 
Pigs were monitored twice daily for any clinical signs and to document any localized 
and or systemic adverse effects. The animals were euthanized with an overdose of 
sodium pentobarbital. A lack of heartbeat was then confirmed by a stethoscope. 
2.4. Results and Discussion 
2.4.1. Protein expression by constructs encoding ASFV antigens 
Codon-optimized synthetic genes encoding p32, p54, pp62, and p72 ASFV antigens 
fused in-frame to FLAG tag were used to generate pcDNA3 constructs, recombinant 
adenoviruses, and recombinant baculoviruses. Immunocytometric analysis of HEK-
293A cells transfected with the pcDNA3 constructs and probed with anti-FLAG mAb 
confirmed expression of each antigen (Fig. 1A). Similarly, HEK-293A cells infected 
with the recombinant adenoviruses and probed with anti-FLAG mAb confirmed protein 
expression (Fig. 1B) and in addition, infected cells probed with the ASFV-specific 
convalescent serum validated that the expressed antigens are authentic (Fig. 1C). The 
recombinant baculoviruses were used to generate affinity-purified recombinant ASFV 
proteins, which were used for ELISA and IFN-γ ELISPOT. We did not generate 
recombinant baculovirus for antigen pp62 since transfection of 293 Freestyle cells with 
the pCDNA construct and subsequent purification yielded sufficient protein for in-vitro 
analyses. The affinity-purified proteins were shown to be authentic by western blot  
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analysis using ASFV-specific convalescent serum (see appendix Fig. A1.) 
 
2.4.2.   Ad-ASFV multi-antigen cocktail rapidly induced robust antibody responses 
2.4.2.1. Post-prime response 
ELISA evaluation of antigen-specific IgM and IgG antibody responses in sera from 
blood collected one week post-priming showed that, all the pigs inoculated with either 
Figure 1. Protein expression by ASFV constructs. 
Protein expression by the constructs encoding ASFV antigens was evaluated by 
immunocytometric analysis of HEK-293A cells. Panels: A) Cells transfected with 
pCDNA3 constructs and probed with anti-FLAG mAb; B) Cells infected with 
recombinant adenoviruses and probed with anti-FLAG mAb; and C) Cells infected with 
recombinant adenoviruses and probed with gamma-irradiated ASFV-specific 
convalescent serum.  Negative controls are mock transfected (A) or mock infected (B & 
C) HEK-293A cells. 
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the 1010 (T1) or 1011 (T2, T3) Ad-ASFV multivalent cocktail dose, but not the negative 
controls (T4), had sero-converted and mounted robust ASFV antigen-specific antibodies 
(Fig. 2).  More importantly, most pigs underwent isotype switching within one week 
based on relatively higher antigen-specific IgG than IgM antibody responses (Fig. 2). 
The IgM and IgG profiles were similar for p32, p54, and pp62 antigens, with no notable 
difference between the 3 treatment groups. However, compared to the pigs immunized 
with the ENABL adjuvant (T1 and T2), the pigs immunized using the Zoetis adjuvant 
(T3) clearly had higher p72 antibody responses, which were IgM dominant. Bi-weekly 
monitoring of antigen-specific IgG responses in each animal showed that the post-prime 
antibody responses peaked anytime between weeks 2 to 8 and gradually declined by 
week 10 in most animals for all antigens (Fig. 3). Not much difference was detected in 
the p32-, p54-, and pp62-specific IgG responses among treatment groups (Fig. 3A-C). In 
contrast, p72-specific IgG responses were highest in T3 animals, slightly lower in T2 
animals and the lowest in T1 vaccinees (Fig. 3D).  One animal in the control group, T4 
had a high anti-p72 IgM and IgG response at week 1 but this response was not detected 
in the subsequent weeks, suggesting that the response at week 1 was non-specific and 
not necessarily primed by the immunization (Fig. 2D and 3D). In addition, adenovirus 
vector-specific IgG responses were generally consistent with the ASFV antigen-specific 
IgG responses (see appendix Fig. A2). Overall, post-prime antibody response data 
clearly showed the ability of the vaccine cocktail to rapidly induce ASFV-specific IgM 
and IgG responses in all vaccinees following single dose inoculation (Figs. 2 and 3).  
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Figure 2. Ad5-ASFV multi-antigen cocktail rapidly primed antibody responses. 
Antigen specific IgMs (lighter shades) and IgGs (darker shades) in sera from week 1 
post-prime were evaluated by ELISA. Color scheme used, T1: Blue; T2: Maroon; T3: 
Green; and T4 (Negative control): Gray. Individual animal response to each antigen was 
evaluated in triplicate and is depicted as the mean of the absorbance values at 450 nm 
minus the mean absorbance of cognate pre-immune sera. The error bars represent the 
standard deviation between triplicates. 
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2.4.2.2 Post-boost response 
The gradual increase in antigen- and vector-specific antibody titers up to 8 weeks post-
priming was an unexpected result and was a critical determinant with respect to the 
administration of the booster dose at week 14 in order to reduce impact due to existing 
adenovirus-specific antibodies. Following boosting, robust antigen-specific recall IgG 
responses against all four antigens were detected in sera collected at weeks 1 - 4 post-
boost (see appendix Fig. A3). Evaluation of antigen-specific end-point titers by ELISA 
in sera collected at week 1 post-boost showed that all vaccinees (T1-T3), but none of the 
Figure 3. Antigen-specific serum IgG profiles post-priming. 
Antigen-specific IgG were monitored biweekly post-prime up to week 10 by ELISA. 
Color scheme used, T1: Blue; T2: Maroon; T3: Green; and T4 (Negative control): Gray. 
The absorbance values at 450 nm across weeks 2, 4, 6, 8 & 10 post-prime for each 
animal are depicted using a color gradient where the lightest shade (first bar) represents 
week 2 and the darkest shade (last bar) represents week 10. Error bars show standard 
deviation among triplicate absorbance values. 
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sham treated controls (T4) had high antibody titers against each antigen (Fig. 4). 
Amongst the four ASFV antigens, pp62-specific titers were the highest and the p72-
specific titers were the lowest (approximately 103 times lower) (Fig. 4). Convalescent 
serum ASFV-antigen specific titers were also evaluated.  The majority of vaccinees had 
p32- and p54-specific titers that were equivalent or higher compared to those in 
convalescent serum (Fig. 4A and 4B), whereas for pp62 only T3 animals had titers equal 
or higher than the convalescent serum (Fig. 4C). However, in contrast, p72-specific titers 
in convalescent serum were higher compared to T1-T3 vaccinees (Fig. 4D). A multiple 
comparison of antigen-specific titers between the three treatment groups showed a 
significant difference only for pp62, with T3 titers significantly higher than both T1 (p< 
0.01) and T2 (p<0.001) (Fig. 4C). A comparison of pre-boost and post-boost ASFV 
antigen-specific antibody responses showed that boosting with the cognate priming dose 
and adjuvant effectively amplified the primary response resulting in high antibody titers 
post-boost (Fig. 4 and A3). Importantly, given that two dose immunization with the Ad-
ASFV multi-antigen cocktail induced titers comparable to the ASFV-specific 
convalescent serum, clearly demonstrates the ability of the multi-antigen cocktail 
formulations to elicit very strong immune responses.  
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Figure 4. ASFV-specific end-point antibody titers. 
Antigen specific end-point titers of sera collected week 1 post-boost were determined by 
ELISA. The endpoint dilution was determined to be the dilution at which the sample OD 
was higher than the OD of cognate pre-bleed +3 standard deviations. Data is represented 
as the reciprocal of the endpoint sera dilution x 106.  The lowest titers were 1:64 x 103 
against p72 and some of the highest titers were as high as 1:16 x 106 against pp62. The 
ASF-specific convalescent serum was also titrated and the titer against each antigen is 
depicted by the red star symbol. Sera from T4 animals showed no reactivity above 
background to any of the antigens (see Fig. A3). The antigen-specific titers amongst the 
treatment groups were compared using ANOVA followed by Tukey’s multiple 
comparison test.  
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A critical role for antibodies in protection against ASFV has not been clearly 
established. Partial to complete protection has been reported following immunization of 
pigs with a combination of recombinant, subunit p30 and p54 antigens [42]. In addition, 
complete protection was reported in another study in which swine were immunized with 
recombinant CD2v (HA) and then challenged with wildtype ASFV [52]. However, in a 
separate study, antibodies induced following a combination of recombinant, subunit p22, 
p30, p54, and p72 antigens did not provide sufficient protection [43]. Furthermore, an 
immunization strategy to avoid ASFV-specific antibody responses by genetic fusion of 
recombinant, subunit p30, p54, and CD2v antigens to ubiquitin conferred protection 
against lethal challenge in a proportion of vaccinees [34]. These disparate findings have 
not allowed the protective role of host antibodies, if any, to be clearly defined during 
virulent ASF infection. Protective role for antibodies in ASFV is strongly supported by 
the observation that passive immunization with anti-ASFV serum confers complete 
protection against a subsequent lethal challenge [53]. Results in the present study using 
an Ad-ASFV multivalent cocktail formulated in two different adjuvants and 
administered in a prime-boost regimen induced detectable antibody titers in 100% of 
immunized pigs and against each of the four ASFV antigens.  
2.4.3. Ad-ASFV multi-antigen cocktail primed antibodies recognized ASF virus 
Indirect Fluorescence Antibody Assay (IFA) and western blot analysis using sera from 
week 1 post-boost confirmed that antibodies induced by the experimental Ad-ASFV 
multi-antigen cocktail recognized intact, native ASFV virus. All Ad-ASFV multi-antigen 
cocktail immunized swine, but none of the sham treated controls, had strong IFA signal 
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against primary swine macrophages infected with the ASFV Georgia 2007/1 isolate (Fig. 
5A).  Overall IFA results strongly demonstrated that the Ad-ASFV multi-antigen 
cocktail induced authentic ASFV-specific antibody responses (Table 2). This outcome 
was also confirmed by western blot using lysates from Vero cells infected with the 
ASFV Georgia 2007/1 isolate. Sera from all the three treatment groups (T1-T3), but not 
the control group (T4), strongly recognized the ASFV antigens (Fig. 5B). A control 
western blot conducted using mock-infected Vero cell lysate showed no background 
reactivity against host cell antigens (see appendix Fig. A4). It is important to note that 
these results do not suggest that the primed antibodies can neutralize ASFV virus, 
however they do confirm that the synthetic genes used to generate the Ad-ASFV 
constructs expressed authentic antigens.  
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Figure 5. The Ad-ASFV multi-antigen cocktail induced authentic ASFV-specific 
antibody responses. 
Indirect Immunofluorescence Antibody assay (IFA) and western blotting using sera from 
week 1 post-boost were used to confirm whether antibodies induced by the experimental 
Ad-ASFV multi-antigen cocktail recognized ASFV infected cells and ASFV-derived 
antigens. Panel A) Primary swine macrophages infected with the ASFV Georgia 2007/1 
isolate and probed with individual, representative sera from six vaccinated and three 
control animals.  ASFV-specific convalescent serum was used as the positive control, 
whereas normal pig serum was used as the negative control. The overall results are 
summarized in Table 2. Panel B) Western blot of lysates from Vero cells infected with 
the ASFV Georgia 2007/1 isolates, probed with sera from all animals. Lane: 1) ASFV 
specific convalescent serum; 2) Normal swine serum. The sera were also tested on mock-
infected Vero cell lysates to check for background reactivity against host cell antigens 
(Fig. A4) 
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2.4.4. Ad5-ASFV multi-antigen cocktail primed antigen specific IFN-γ-secreting cells 
ASFV antigen-specific IFN-γ-secreting cells were detected in whole peripheral blood 
mononuclear cells (PBMCs) post-prime and post-boost by IFN-γ ELISPOT assays (Fig. 
6).  Post-prime, majority of pigs in the three treatment groups (T1-T3) had higher IFN-γ 
responses against p54 and pp62 antigens compared to p32 and p72 antigens.  Notably, 
the p54-specific IFN-γ responses were significantly higher in T1 pigs (p<0.05) and in T2 
pigs (p<0.01) compared to the T4 sham treated controls (Fig. 6A).  In addition, pp62-
specific IFN-γ responses were significantly higher in T2 pigs (p<0.001) compared to the 
T4 controls (Fig. 6A). Antigen-specific IFN-γ recall responses observed in PBMCs three 
weeks post-boost, most notably the p32 and p72-specific responses, highlighted the 
booster dose effect (Fig. 6B). Compared to the T4 sham treated controls, significantly 
higher (p<0.05) IFN-γ responses against p32, pp62, and p72, but not p54, were observed 
in T1, but not in T2 and T3 animals (Fig. 6B). Post-boost, T1 pigs had higher, detectable 
IFN-γ responses against all four antigens tested compared to the other two treatment 
groups. This result differs from the post-prime results in which T2 immunized pigs were 
overall the best responders (Fig. 6A and 6B).  One possibility for the discordant post-
prime and post-boost results may be due to the relatively higher anti-adenovirus titers in 
T2 versus T1 at the time of boost which reduced the overall effectiveness of the booster 
dose in T2.  
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Figure 6. ASFV antigen-specific IFN-γ responses post-prime and post-boost. 
The frequency of antigen-specific IFN-γ-secreting cells in PBMCs induced A) two weeks 
post-prime B) three weeks post-boost was evaluated by IFN-γ ELISPOT. The response is 
presented as IFN-γ Spot Forming Cells (SFC)/106 PBMCs.  The mean response of 
treatment groups (T1-T3) was compared to the mean response of the sham treated control 
group (T4) using ANOVA followed by Bonferroni’s multiple comparison test. 
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ELISPOT assays performed at study termination (week 8 post-boost) using 
isolated splenocytes confirmed the presence of antigen-specific IFN-γ-secreting memory 
cells. Notably, strong IFN-γ+ responses against the four ASFV antigens were detected 
(Fig. 7). Compared to the T4 controls, significantly higher p32-specific IFN-γ+ 
responses were detected in T1 (p<0.01) and T2 (p<0.05) swine (Fig. 7). Significant 
(p<0.01) p54-specific IFN-γ+ responses were only detected in T1 animals, whereas, 
significant (p<0.01) pp62-specific IFN-γ+ responses and (p<0.05) p72-specific IFN-γ+ 
responses were only detected in T2 animals (Fig. 7).  
Figure 7. ASFV antigen-specific IFN-γ recall responses in spleen.  
Presence of antigen-specific IFN-γ secreting memory T-cells in the spleen at study 
termination (week 8 post-boost) was evaluated by IFN-γ ELISPOT assay as above. The 
response is presented as IFN-γ Spot Forming Cells (SFC)/106 Splenocytes. Statistical 
analysis was done as described in Fig. 6. 
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A recent study using BacMams expressing a p30-p54-CD2v chimera reported 
partial protection upon sub-lethal challenge and a direct correlation between protection 
and induction of ASFV-specific IFN-γ+ T-cells [54]. In this study, strong IFN-γ+ 
peripheral and splenic tissue responses were elicited against each antigen in the Ad-
ASFV multi-antigen cocktail in the majority of immunized swine (T1-T3) following 
prime-boost. Taken together, the ASFV antigen-specific IFN-γ responses observed in 
this immunogenicity study are promising and support the need to evaluate their potential 
to confer protection in a challenge study.  
2.4.5. Ad5-ASFV cocktail primed antigen-specific Cytotoxic T Lymphocytes (CTLs) 
One round of in vitro re-stimulated PBMCs (T1-T3) isolated 4 weeks post-boost were 
shown to effectively lyse autologous skin fibroblast transfectants in an ASFV antigen-
specific manner at defined effector-target (E:T) ratios in 51Cr-release assays (Fig. 8).  
Lytic activity against autologous skin fibroblast transfected with a construct expressing 
an FMDV negative control antigen remained at 20% or less for all animals, thus 
validating that the lytic activity observed against ASFV antigens can be attributed to 
ASFV antigen-specific CTLs and not non-specific NK cells (Fig. 8).  Stimulation of the 
PBMCs for an additional round to further enrich CTLs failed to increase CTL activity, 
possibly due to activation-induced death of effectors. Among the T1-T3 immunized 
swine, the level of antigen-specific lysis was equivalent in T1 and T3 and lower in T2.  
This result is consistent with the post-boost observation discussed earlier in which 
relatively higher anti-adenovirus titers in T2 versus T1 at the time of boost may have 
reduced the overall effectiveness to amplify the primed CD8+ T-cell responses.   
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Figure 8. Ad5-ASFV multi-antigen cocktail primed ASFV antigen-specific 
Cytotoxic T Lymphocytes (CTL) responses. 
Antigen specific CTL responses in PBMCs collected post-boost (week 4) were evaluated 
at effector to target ratios of 50:1 and 25:1 using the standard 51Cr release assay. Data is 
represented as % specific lysis against each ASFV antigen and a FMDV negative control 
antigen.  Representative data for 2 animals from treatment groups T1, T2 and T3 is 
shown. Assays were not conducted for animals from the control group, T4. 
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The heterogeneous CTL responses observed within the context of the study and 
assay designs are consistent with expected outcomes from the outbred commercial pigs 
used.  This study is the first to demonstrate induction of ASFV antigen-specific CTL 
responses in commercial swine using Ad-ASFV multi-antigen cocktail, but will require 
further evaluation in subsequent studies using ASFV-infected target cells.  
Substantial evidence in published literature emphasizes the importance of CTLs 
in protection against ASFV. Studies have shown that ASFV-specific CTLs can be 
induced in swine infected with live, attenuated ASFV and the primed CTLs were shown 
to be responsible for clearance of infected cells [32]. Significant proportions of ASFV-
specific CD4+CD8high+ CTLs have been detected in immune swine that are protected 
from clinical disease than from immune but clinically diseased pigs, suggesting that 
these CTLs are required for disease control [28]. Furthermore, depletion of CD8+ T-cells 
in swine results in loss of protective immunity to ASFV infections [33]. Within this 
context, the CTL results reported herein are noteworthy and clearly demonstrate the 
ability of a replication-deficient viral vectored ASFV multi-antigen cocktail to induce 
antigen-specific CTLs that are capable of recognizing and lysing autologous ASFV-
antigen presenting fibroblasts.  
2.4.6. Ad5-ASFV cocktail was well tolerated  
Following inoculation of the Ad-ASFV multi-antigen cocktail, both the 1010 and the 1011 
doses and adjuvant formulations (Table 1) were reasonably well tolerated in all the 
swine.  Although no adverse systemic effects or injection site reactions were observed, 
some pigs in T1, T2 and T4 that received the ENABL formulation had mild injection site 
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swelling, were transiently depressed (lethargic) and had reduced appetite for two days 
following the booster dose. T3 vaccinees (Zoetis adjuvant) were active but all had a pink 
discoloration at the injection site.  However, by the 3rd day post-boost, all the swine were 
active, healthy and with good appetite, and remained so for the rest of the study period.  
Thus, overall, the Ad-ASFV multi-antigen cocktails formulated at both doses and with 
both adjuvants were safe and well tolerated by all the swine.  
2.5. Conclusions 
The ASFV is a large complex DNA virus encoding >150 proteins. Experimental, subunit 
vaccines based on a few of these antigens have generated different protective outcomes, 
demonstrating that these antigens do play some role in host protection. Immunization of 
animals with an expression library of restriction enzyme digested ASFV genome 
fragments protected 60% of the animals [55]. This outcome suggests that protection 
through subunit vaccines is feasible, but is unlikely to be highly efficacious using a 
single or only a few antigens. Empirical identification of antigens necessary for inducing 
a protective response, along with a suitable antigen delivery system that elicits strong 
cellular as well as humoral responses may be a reasonable strategy to develop an 
efficacious, prototype ASFV vaccine. The immunogenicity data generated from this 
proof-of-concept study showed that the replication-deficient adenovirus vector, dose, 
adjuvant formulation and the immunization regimen effectively induced strong antibody 
(with unprecedented rapid isotype-switching) and cellular responses against four ASFV 
antigens.  An analysis of the overall differences in antibody and T-cell immune response 
observed across the three differential treatment groups revealed some interesting 
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outcomes. In case of the humoral responses, the T3 animals (immunized with the Zoetis 
adjuvant) had a slightly higher antibody response, however the end-point titration data 
(Fig. 4) failed to demonstrate any significant differences in the titers amongst the three 
treatment groups for three of the four ASFV antigens tested (pp62 was the only 
exception). With respect to T-cell mediated immune responses, the post-prime antigen-
specific IFN-γ response clearly showed that T2 (high dose, ENABL adjuvant) animals 
were the best overall responders. However, the post-boost data suggests that the low 
dose prime and low dose boost (T1) had the highest recall response. Based on this 
outcome, it may be useful in future immunogenicity and efficacy studies to test whether 
priming with the low dose (1010 IFU/Ad-ASFV construct) and boosting with the high 
dose (1011 IFU/Ad-ASFV construct) will elicit better immune responses. In addition, 
there is merit to testing both adjuvants in future efficacy studies to better understand the 
relevance of the varied immune responses induced in context of the protection conferred. 
In conclusion, an Ad-ASFV multi-antigen cocktail two dose formulation was 
immunogenic and safe when administered in a prime-boost regimen.  Results showed 
evidence of rapid post-prime antibody class switching, induction of robust antibody 
responses which recognize ASFV-infected cells, and the generation of antigen-specific 
IFN-γ and antigen-specific CTL responses to all four ASFV antigens. The 
immunogenicity data from this study validates our approach of using an adenovirus-
vectored cocktail of ASFV antigens and sets the stage for conducting future challenge 
studies using a cocktail of the above antigens as well as other novel ASFV antigens. 
Collectively, these data validate a synthetic gene-based approach to generate ASFV 
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antigen delivery constructs and provide a rational strategy for further screening of ASFV 
antigen targets toward development of a DIVA compatible, multi-antigen, efficacious 
ASF vaccine.  
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CHAPTER III                                                                                                              
ADENOVIRUS-VECTORED NOVEL AFRICAN SWINE FEVER VIRUS 
ANTIGENS ELICIT ROBUST IMMUNE RESPONSES IN SWINE 
3.1. Overview 
African Swine Fever Virus (ASFV) is a high-consequence Transboundary Animal 
pathogen that often causes hemorrhagic disease in swine with a case fatality rate close to 
100%.  Lack of treatment or vaccine for the disease makes it imperative that safe and 
efficacious vaccines are developed to safeguard the swine industry. In this study, we 
evaluated the immunogenicity of seven adenovirus-vectored novel ASFV antigens, 
namely A151R, B119L, B602L, EP402RΔPRR, B438L, K205R and A104R. 
Immunization of commercial swine with a cocktail of the recombinant adenoviruses 
formulated in adjuvant primed strong ASFV antigen-specific IgG responses that 
underwent rapid recall upon boost. Notably, most vaccinees mounted robust IgG 
responses against all the antigens in the cocktail. Most importantly and relevant to 
vaccine development, the induced antibodies strongly recognized Georgia 2007/1 
ASFV-infected cells by IFA and the actual ASF viral proteins by western blot analysis. 
The recombinant adenovirus cocktail also induced ASFV-specific IFN-γ-secreting cells 
that were recalled upon boosting. Evaluation of local and systemic effects of the 
recombinant adenovirus cocktail post-priming and post-boosting in the immunized 
animals showed that the immunogen was well tolerated and no serious negative effects 
were observed. Taken together, these outcomes showed that the adenovirus-vectored 
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novel ASFV antigen cocktail was capable of safely inducing strong antibody and IFN-γ+ 
cell responses in commercial swine.  The data will be used for selection of antigens for 
inclusion in a multi-antigen prototype vaccine to be evaluated for protective efficacy. 
3.2. Introduction 
The African Swine Fever Virus (ASFV) is a high-consequence Transboundary Animal 
Disease (TAD) pathogen that causes hemorrhagic fever in swine and has mortality rates 
approaching 100% [20].  There is no vaccine or treatment available for this disease. The 
ASFV causes major economic losses in endemic areas and poses a high risk to swine 
production in non-affected areas as it continues to spread globally [22]. Therefore, it is 
imperative that appropriate counter-measures are developed to reduce the prevalence of 
this disease in endemic areas, prevent further outbreaks in affected countries and 
safeguard the swine industries in non-affected areas.  
                Development of an efficacious vaccine for ASFV is still a challenge. There is 
strong evidence to suggest that protection against ASFV can be induced since attenuated 
virus has been shown to protect against parental or closely related virulent isolates [26, 
27, 56]. Attenuated vaccines, however, are yet to be rigorously tested in the field in 
readiness for deployment. Development of an affordable DIVA (Differentiating Infected 
from Vaccinated Animals) ASFV subunit vaccine is a more attractive option, especially 
for use in non-endemic areas, in case of an outbreak.  
                 Subunit vaccines based on one or two ASFV antigens have so far failed to 
induce immunity strong enough to confer significant protection among vaccinees, [34, 
42, 43, 54] but, immunizing swine with DNA plasmids expressing a library of restriction 
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enzyme digested ASFV-genome fragments conferred protection in a majority (60%) of 
the vaccinees against lethal challenge [55]. This result, though in favor of developing 
subunit based vaccines for ASFV, also highlights the main challenges associated with 
developing subunit vaccines: identification of protective antigens as well as a suitable 
delivery vector to induce strong protective responses. It is envisaged that successful 
development of an effective subunit vaccine will require empirical identification and 
validation of multiple suitable antigens that will induce significant protection in majority 
of the vaccinees.  
                We have previously shown that immunizing swine using a cocktail of 
replication deficient adenoviruses expressing ASFV antigens p32, p54, pp62, and p72 
elicited robust antigen-specific antibody, IFN-γ+ cellular and cytotoxic T-lymphocyte 
(CTL) responses [57]. We used replication-incompetent human adenovirus (Ad5) vector 
since it is safe, gives high protein expression levels and replicates at high titers in 
completing cells making production scalable and reproducible [4, 5]. In addition, 
efficacy of adenoviruses in swine immunizations has previously been demonstrated in 
the successful development of a recently USDA-licensed recombinant Foot and Mouth 
Disease vaccine [16, 58]. In this study, we evaluated immunogenicity of seven ASFV 
vaccine candidates selected based on published literature (Table 3).  
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Table 3: Antigens Selected for Evaluation of Immunogenicity   
Gene/Antigen Functional Characteristics /Immune Relevance Reference 
A151R Essential for the virus replication and morphogenesis. 
May play a role in viral transcription. 
[59] 
B119L Critical for virus assembly. 90% of deletion mutants are 
crippled and fail to generate viable viral particles  
[27], [60] 
B602L Chaperone for p72 (major capsid protein), repression 
leads to decrease of p72 expression, inhibition of pp220 
and pp62 processing.  Deletion severely alters viral 
assembly. Recognized by domestic pig and bush pig 
hyper-immune sera   
[61] , [62], 
[63], [64].   
EP402R ASFV Hemagglutinin. Extracellular domain contains 
protective T-cell epitopes. Protective immunity against 
homologous infection maybe haemadsorption inhibition 
(HAI) serotype-specific.  
[65], [34], 
[66], [67] 
B438L Required for formation of vertices in icosahedral capsid [68] 
K205R Induces strong antibody responses, but ability to elicit 
T-cell responses has not been tested. Recognized by 
domestic pig and bush pig hyper-immune sera 
[63], [64] 
A104R Histone-like protein. Primes strong antibody responses, 
mainly detected in asymptomatic than chronically 
infected pigs.  Presence of T-cell determinants has not 
been evaluated. 
[69], [64] 
 
The ability of these antigens to induce antibody and T-cell responses in 
commercial swine has not been evaluated so far. The antigen, EP402R, has been 
previously evaluated, however, only the extracellular domain was included and 
expressed as a fusion chimera along with other ASFV antigens, p32 and p54. In this 
study, we altered the EP402R protein sequence to delete the proline-rich repeats in the 
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cytoplasmic tail and the resultant protein was designated EP402RΔPRR. The proline-
rich repeats have been shown to interact with the adaptor protein SH3P7 in host cells and 
it is theorized that this interaction could, in part, be responsible for the 
immunomodulatory role of the EP402R protein [70]. Thus, deletion of the proline-rich 
repeats is expected to abrogate immunomodulatory effects when the EP402R protein is 
included in a multi-antigen subunit vaccine.  
              The focus of this work was to evaluate the immunogenicity of seven novel 
ASFV antigens, in commercial swine using replication-deficient adenovirus as a delivery 
platform with an end goal of identifying candidates for rationally designing a prototype 
multi-antigen ASFV subunit vaccine.  
3.3. Materials and Methods 
3.3.1. Generation of recombinant adenoviruses expressing ASFV antigens 
The amino acid sequences of the ASFV antigens (Georgia 2007/1 isolate) were obtained 
from Genbank (Accession FR682468). The EP402RΔPRR sequence was generated by 
deleting the proline-rich repeats from the EP402R cytoplasmic domain [70]. Since 
K205R and A104R polypeptides are short, they were fused in frame to generate a 
chimeric sequence, designated K205R-A104R. The sequences of the target antigens 
(A151R, B119L, B602L, EP402RΔPRR, B438L, and K205R-A104R) were then 
modified to add, in-frame, a FLAG- and HA- tag at the N- and C-termini, respectively, 
and the resultant protein sequences were used to generate synthetic genes which were 
codon-optimized for protein expression in swine. Synthesis, codon-optimization, cloning 
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in pUC57 vector, and sequence-verification of these genes was outsourced (GenScript, 
NJ, USA). Each gene was then amplified by PCR using attB1-FLAG specific forward 
and attB2-HA specific reverse primers and subcloned into Gateway pDonR221 vector 
(Invitrogen) as per manufacturer’s protocols. Positive pDonR clones were validated by 
sequencing and used to transfer the gene cassette into the adenovirus backbone vector, 
pAd/CMV/V5-DEST (Invitrogen) by homologous recombination. Validated positive 
pAd clones were then used to generate recombinant adenoviruses, designated AdA151R, 
AdB119L, AdB602L, AdEP402RΔPRR, AdB438L, and AdK205R-A104R, using the 
ViraPower Adenoviral Expression System (Invitrogen). Antigen expression by the 
adenoviruses was confirmed by immunocytometric analysis of infected Human 
Embryonic Kidney (HEK)-293A cells. The viruses were scaled up to generate bulk 
stocks for immunization and titrated (infectious focus units, IFU) in HEK-293A cells as 
previously described [57]. A recombinant adenovirus expressing luciferase, designated 
Ad-Luc, was similarly prepared and served as a negative control immunogen.  
3.3.2. Generation of recombinant ASFV antigens 
The genes encoding the A151R, B602L, EP402RΔPRR, B438L and K205R-A104R 
antigens were PCR amplified from the respective pDonR clones using FLAG-specific 
forward and HA-specific reverse primers. The resultant PCR products were cloned into 
the pFastBac™ HBM TOPO shuttle vector (Invitrogen). Positive clones were identified 
by PCR screening and used to generate recombinant baculoviruses using the Bac-to-Bac 
HBM TOPO Secreted Expression System (Invitrogen). Protein expression by the 
generated viruses was confirmed by immunocytometric analysis of infected Sf-9 cells. 
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One clone of each baculovirus was then scaled up and used to infect High Five cells 
(Invitrogen) to generate recombinant proteins. These proteins were affinity-purified 
using the anti-FLAG M2 affinity gel (Sigma, A2220). Recombinant B119L was affinity 
purified similarly, but from AdB119L-infected HEK-293A cell lysates. 
3.3.3. Validation of protein expression 
3.3.3.1. Immunocytometric analysis 
Protein expression by the recombinant adenoviruses was evaluated by 
immunocytometric analysis as described previously [48]. Briefly, HEK-293A cell 
monolayers infected with the adenoviruses were incubated with a gamma-irradiated 
ASFV-specific convalescent serum (1:250 dilution) [57]. Following 3X washes, the cells 
were further incubated with a 1:500 dilution of alkaline phosphatase-conjugated goat 
anti-porcine IgG (Southern Biotech, Cat# 6050-04) for 1 hr. Following washes as above, 
Fast Red TR–Naphthol AS-MX substrate (Sigma, F4523) was added to the cells to 
detect the alkaline-phosphatase activity. Protein expression by the recombinant 
baculoviruses was similarly evaluated by infecting Sf-9 cells. Mock infected cells served 
as negative controls.  
3.3.3.2. Western blot 
Affinity-purified recombinant proteins (A151R, B119L, B602L, EP402RΔPRR, B438L, 
and K205R-A104R) were resolved by SDS-PAGE and transferred to Immobolin-P 
PVDF Membrane (Fisher Scientific). Following an overnight incubation at 4°C with 
blocking buffer (10% non-fat dry milk TBST), the membrane was incubated with 
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ASFV-specific convalescent serum (1: 2,500 dilution in blocking buffer) for 1hr. The 
membrane was then washed 3X with TBST and incubated with peroxidase-conjugated 
Goat anti-swine IgG (1:5,000) (Jackson ImmunoResearch, Cat #114-035-003). 
Chemiluminescence was detected by the SuperSignal West Pico PLUS substrate 
(Thermo Scientific, Prod #34577). 
3.3.4. Swine immunizations  
Twenty weaned swine were randomly distributed into the treatment and control groups 
(n=10). The treatment group was immunized with the Ad-ASFV cocktail (1 X 1011 IFU) 
of each construct (formulated in ENABL adjuvant (Benchmark Biolabs, Cat# 7010106-
C6)). The control group received Ad-Luc formulated as above. The inoculum was 
injected intramuscularly in the neck area behind the ears. The animals were then boosted 
similarly after 8 weeks. Blood was collected for sera and PBMC isolation once pre-
immunization and then biweekly post-prime, and then weekly post-boost for 3 weeks to 
run ELISAs and IFN-γ ELISPOTs. The animals were euthanized at 4 weeks post-boost.  
3.3.5. ELISA 
Antigen-specific antibody responses were evaluated by a direct ELISA as previously 
described [57]. Briefly, microplates coated overnight at 4°C with 100 μl of 1μg/ml of 
affinity-purified antigen in bicarbonate coating buffer were washed and blocked with 
10% non-fat dry milk in PBS with 0.1% Tween 20 for 1 hr. Sera were diluted at 1:100 
(week 4 post-prime) or 1: 8,000 (week 2 post-boost) in blocking buffer and added at 100 
μl per well in triplicates.  After incubation for 1 hr. at 37°C, the plates were washed and 
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incubated for another hr. with 100 μl/well of a 1: 5,000 dilution of peroxidase-
conjugated anti-swine IgG (Jackson ImmunoResearch, Cat# 114-035-003). Following 
washes, the plates were developed with Sure Blue Reserve TMB substrate (KPL, Cat# 
53-00-02) and reaction was stopped using 1N Hydrochloric acid.  The IgG response by 
each animal to each antigen was calculated as mean absorbance of test sera minus the 
mean absorbance of the cognate pre-immunization sera. To determine antigen-specific 
IgG end-point titers, sera from blood collected two weeks post-boost was serially diluted 
two-fold starting at 1: 4,000 up to 1: 4 X 106. The pre-immunization serum was similarly 
diluted. The end-point titer was calculated as described previously [57].  
3.3.6. Indirect Fluorescence Antibody Assay (IFA) 
Pretreated Teflon coated slides with fixed ASFV (Georgia 2007/1)-infected and mock-
infected Vero cells (ATCC CCL-81) were used to perform the IFA as previously 
described [11]. Briefly, the slides were incubated with sera from two weeks post-boost 
diluted 1:250 for 1 hr. at 37°C.  ASFV-specific convalescent serum (1:10,000) was used 
as a positive control and normal swine serum (1:250) (GIBCO) was used as a negative 
control.  Following extensive washes with D-PBS, the wells were incubated with FITC-
conjugated goat anti-swine sera (Kirkegaard and Perry Cat No. 02-14-02) for 45 minutes 
at 37°C, washed again and mounted with Prolong Gold antifade reagent with DAPI 
(Invitrogen, Cat. No. PT389868).  The cells were visualized using an Olympus immuno-
fluorescent microscope (model BX-40) and photographed by an Olympus digital camera 
(model DP 70). The IFAs were conducted at Plum Island Animal Disease Center. 
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3.3.7. Western blot with ASFV-infected cell lysates 
Lysates from ASFV Georgia 2007/1 (Vero cell-adapted)-infected Vero cells were used 
to perform a western blot as previously described [57].  Briefly, the prepared cell lysates 
were electrophoresed on a NuPAGE 4-12% Bis-Tris Gel (1.0mm X 2D well) for 35 
mins, followed by transfer to 0.2um PVDF membranes (Invitrogen #LC2002) for 1 hour.  
The membranes were then blocked for 1 hr. in blocking buffer (PBST+5% non-fat dry 
milk) and transferred to the Protean II Slot-Blotter.  Sera from week 2 post-boost were 
diluted 1:50 in blocking buffer and added to individual wells for 1 hr. at room 
temperature with shaking.  After washing the wells 3X with PBST, the membranes were 
removed from the blotting apparatus and incubated for 1 hr. with a 1: 2,000 dilution of 
Goat anti-swine-HRP (KPL #14-14-06).  Following washes, the membranes were 
developed using DAB (Sigma #D4293).  ASFV-specific convalescent serum (1:10,000) 
was used as a positive control and normal swine serum (GIBCO) was used as a negative 
control.  Background reactivity to host-cell antigens was gauged similarly using mock-
infected lysates. The western blot analysis was carried out at Plum Island Animal 
Disease Center.  
3.3.8. IFN-γ ELISPOT assays  
Antigen-specific IFN-γ+ cell response was evaluated by an enzyme-linked immunospot 
(ELISPOT) assay using the Mabtech kit (Cat# 3130-2A), as per manufacturer’s 
instructions and as previously described [57].  Briefly, whole blood-derived PBMCs 
resuspended in complete RPMI-1640 media were added to wells of MultiScreen-HA 
plates (Millipore) at a density of 250,000 cells/well.  Affinity-purified antigens were 
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added to the cells at a final concentration of 2.5 μg/ml in triplicates. Phytohemagglutinin 
(PHA) mitogen (5 μg/ml) was used as a positive control, whereas media served as the 
negative control.  The spots were counted by an ELISPOT reader and AID software 
(AutoImmun Diagnostica V3.4, Strassberg, Germany).  The mean number of IFN-γ+ 
Spot-Forming Cells (SFC) for each sample was calculated by subtracting the mean 
number of spots in the negative control wells from the mean number of spots in the 
sample wells.  The data is presented as mean number of SFC per 106 PBMCs.  
3.3.9. Statistical analysis 
The differences in the mean antigen-specific antibody and IFN-γ+ responses between the 
treatment and the control group were analyzed by an unpaired t-test with Welch’s 
correction, and a P value of ≤0.05 was considered significant. The analysis was 
performed with GraphPad Prism Version 6.05 using a significance level of P<0.05. 
3.3.10. Ethics statement 
All animal procedures were conducted as per the Animal Use Protocol 2014-0020, 
reviewed and approved by the Texas A&M University Institutional Animal Care and 
Use Committee (IACUC). The Texas A&M IACUC follows the regulations, policies and 
guidelines outlined in the Animal Welfare Act (AWA), USDA Animal Care Resource 
Guide and the PHS Policy on Humane Care and Use of Laboratory Animals. At the 
termination of the study, the animals were euthanized with an overdose of sodium 
pentobarbital. 
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3.4. Results and Discussion 
3.4.1. Recombinant constructs encoding ASFV antigens 
Codon-optimized synthetic genes encoding antigens, A151R, B119L, B646L, 
EP402RΔPRR, B438L, and K205R-A104R fused in-frame to FLAG and HA tags were 
used to generate recombinant adenoviruses designated AdA151R, AdB119L, AdB602L, 
AdEP402RΔPRR, AdB438L, and AdK205R-A104R.  The immunogenicity of K205R and 
A104R was evaluated as a chimera since both proteins are relatively small (~20kDa and 
~10kDa) and delivering them in vivo as a chimera would reduce the number of 
adenoviruses to be inoculated. Evaluation of protein expression by immunocytometric 
analysis of adenovirus-infected HEK-293A cells using ASFV-specific convalescent serum 
showed that the assembled recombinant adenoviruses expressed the encoded antigens (Fig. 
9A).  The synthetic ASFV genes were also used to generate recombinant baculoviruses for 
generation of affinity-purified recombinant proteins needed for in vitro evaluation of 
antigen-specific antibody and cell responses.  However, despite several attempts, we were 
unsuccessful in generating a recombinant baculovirus expressing B119L and thus we used 
affinity-purified antigen from AdB119L-infected HEK-293A cells for in-vitro readouts. 
The authenticity of the affinity-purified recombinant proteins was validated by western blot 
using ASFV-specific convalescent serum (Fig. 9B). A very faint band (depicted by an 
arrow) was observed for antigen B438L at the expected molecular weight (~50 KDa). The 
antigen loads were optimized for signal detection. However, for antigen B438L the signal 
intensity remained weak despite increasing antigen load to microgram quantities. This 
could be due to low B438L-specific antibodies in the ASFV-specific convalescent serum, 
 51 
 
also evidenced by the low anti-B438L end point titer of 1:4000 observed by ELISA (see 
Fig. 11).   
Figure 9. Validation of protein expression by ASFV constructs.                                                 
The authenticity of the ASFV antigens expressed by the constructs was confirmed by 
immunocytometric and western blot analysis using gamma-irradiated ASFV-specific 
convalescent serum. Panels: A) HEK-293A cells infected with recombinant 
adenoviruses; and B) A western blot of the affinity purified ASFV proteins probed with 
the convalescent serum. Lane: 1) Mwt marker in kDa; 2) A151R; 3) B119L; 4) B602L; 
5) EP402RΔPRR; 6) B438L and 7) K205R-A104R chimera. The arrow points to the faint 
band detected for B438L (the signal intensity of the band increased with longer exposure 
times). 
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3.4.2. Ad5-ASFV cocktail primed ASFV antigen-specific antibodies 
Twenty commercial swine were randomly divided into two groups (n=10).  The 
treatment group was immunized with a cocktail of six recombinant adenoviruses 
expressing the A151R, B119L, B602L, EP402RΔPRR, B438L, and K205R-A104R 
ASFV antigens, whereas the negative control group received Ad-Luc sham treatment. 
After priming, antigen-specific IgG responses were detected in a majority of swine in the 
treatment group, but not the control group.  Data from sera analyzed four weeks post-
priming is shown (Fig. 10A).  
 
The mean response of the treatment group was significantly higher than the 
control group for antigens A151R (p<0.001), B119L (p<0.01), B602L (p<0.001), B438L 
Figure 10. Mean antigen-specific IgG responses post-priming and post-boost. 
Antigen-specific IgG response was evaluated post-prime and post-boost by ELISA. A) 
Sera from week 4 post-prime were evaluated at a 1:100 dilution. B) Sera from week 2 
post-boost were evaluated at a 1:8,000 dilution (to prevent the absorbance values from 
going out of range). The error bars represent the SEM. The asterisks denote a significant 
difference between the mean response of the treatment and control animals. *p<0.05, 
**p<0.01, ***p<0.001. 
 53 
 
(p<0.05) and K205R-A104R (p<0.001). The mean antibody response against the 
EP402RΔPRR antigen by the swine in the treatment group was slightly higher than the 
controls but not significant.  The strong mean responses observed against antigens 
B602L and K205R-A104R is consistent with previous studies where these antigens have 
been shown to be strongly recognized by domestic pig and bush pig hyper-immune sera 
[63, 64].  Following boosting at 8 weeks post-priming, antigen-specific recall IgG 
responses against all antigens were detected in the animals in the treatment group (Fig. 
10B). The mean response of the treatment group was significantly higher than the 
control group for antigens A151R (p<0.01), B119L (p<0.001), B602L (p<0.05), 
EP402RΔPRR (p<0.05), and K205R-A104R (p<0.01), but not for antigen B438L. It is 
important to note that the responses at week 2 post-boost were evaluated at 1:8,000 sera 
dilution, whereas the responses post-prime were evaluated at a 1:100 sera dilution (Fig. 
10).  This eliminated the background responses observed against some antigens post-
prime in the control group. However, for antigen B119L, the control group still had a 
low-level of background reactivity after boosting.  This background response could be 
attributed to vector-specific antibodies since the affinity-purified B119L antigen was 
derived from lysates of AdB119L-infected HEK-293A cells.  Also the response seen in 
the treatment group is likely to be inclusive of a low level of vector-specific antibodies.  
Evaluation of antigen-specific end-point titers post-boost in the immunized pigs showed 
that a majority of the vaccinees had titers ≥ 1:256 x 103 against antigens A151R, B119L, 
B602L, and K205R-A104R (Fig. 11).  The highest titer was 1:2 x 106 against B602L in 
one of the vaccinees (Fig. 11).  A comparison of the antigen-specific titers in sera from 
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the vaccinees with the titer of the ASFV-specific convalescent serum revealed that Ad-
ASFV cocktail was able to induce titers higher or equivalent to the convalescent serum 
in a majority of animals for antigens B119L (90% of vaccinees), B438L (90% of 
vaccinees), B602L (80% of vaccinees), and EP402RΔPRR (80% of vaccinees). This is a 
noteworthy result, since these animals received only two immunizations of the Ad-
ASFV cocktail, whereas the positive control convalescent serum came from an animal 
that received multiple inoculations of live ASFV [57]. However, for antigen, K205R-
A104R only 3 of 10 vaccinees had titers that matched up to the convalescent serum, 
whereas for antigen, A151R the titers induced in the vaccinees did not match up to the 
convalescent serum.  
The role of antibodies in ASFV protection is not yet completely understood [35]. 
Protection reported by passively acquired anti-ASFV antibodies, however, is strong 
evidence in favor of antibodies and supports the evaluation of humoral responses in 
immunogenicity studies focused on identification of novel targets for subunit vaccine 
development [53, 71]. In the current study, a cocktail of replication-incompetent 
adenovirus constructs expressing multiple ASFV antigens primed strong antibody 
responses against all antigens in a majority of the animals.   
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Figure 11. Antigen-specific end-point IgG titers.  
Antigen specific antibody titers, determined by ELISA, in sera from treatment group 
animals (T) collected two weeks post-boost. The dilution of the sera at which the 
absorbance reading was higher than that of the cognate pre-bleed +3 standard 
deviations is reported as the end-point titer. The ASFV-specific convalescent serum 
was titrated similarly and is represented by the red star symbol (S). Data is represented 
as the reciprocal of the end-point sera dilution x 106. For antigen B119L, the sera from 
control group animals was also titrated to gauge background reactivity to host-cell and 
vector-derived antigens. An average of the titers of the control group animals was then 
subtracted from the titer of each treatment group animal to give B119L-specific titers. 
For the remaining antigens, the post-boost sera from the control group animals showed 
no reactivity as seen in Fig. 10B. 
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3.4.3. Antibodies primed by the Ad5-ASFV cocktail recognized ASF virus 
Indirect Immunofluorescence Antibody Assay (IFA) performed with sera from blood 
collected from the vaccinees two weeks post-boost, confirmed that the antibodies primed 
by the Ad5-ASFV cocktail recognized Vero cells infected with the actual ASF virus 
(Georgia 2007/1 isolate) but not mock-infected cells (Fig. 12A).  Sera from 8 out of 10 
swine in the treatment group, but none from the controls, recognized the ASFV-infected 
cells (Table 4).  Sera from 2 animals (swine 89 and swine 91) were most reactive and 
reacted with the plasma membrane, a virus factory like structure and general cytoplasm. 
western blot analysis of ASFV-infected Vero cell lysates probed with the post-boost sera 
also validated the above results (Fig. 12B). This outcome showed that synthetic genes 
encoding antigens of ASFV (a Risk Group 3 pathogen) that requires BSL3 
biocontainment can safely be used at BSL2 level to develop and test immunogenicity 
and tolerability of prototype ASFV vaccines. These results, however do not directly 
demonstrate that the ASFV antigen-specific antibodies have functional activity. In case 
of ASFV, it is generally acceptable in the scientific community, that conventional plaque 
reduction assay to measure ASFV antibody neutralization activity is technically difficult 
since low-passage (virulent) ASFV strains show no or a significant delay in plaque 
formation, and is especially difficult to conduct the assay in primary swine macrophage 
cells.  A highly attenuated ASFV Georgia strain that is adapted to a suitable cell line 
(e.g., Vero cells), or a genetically modified ASF virus expressing a chromogenic marker 
gene, for use in testing study samples for virus neutralization activity was not available 
at the time the study was conducted. 
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Figure 12. Antibodies primed by the Ad-ASFV cocktail recognized ASF virus. 
Analysis of sera from two weeks post-boost by Indirect Immunofluorescence Antibody 
assay (IFA) and western Blot showed that the antibodies primed by the Ad-ASFV 
cocktail recognized the parental ASFV infected cells and ASFV-derived antigens. Panel 
A) Vero cells infected with ASFV Georgia 2007/1 probed with sera from treatment and 
negative control animals. ASFV specific convalescent serum was used as the positive 
control and normal swine serum served as the negative control. Data for three animals 
(that gave the strongest reaction) from the treatment group and one animal from the 
control group is shown. A summary of IFA results for all animals is presented in Table 
4; B) Lysates from Vero cells infected with ASFV Georgia 2007/1 isolate were blotted 
and probed with sera from all animals; Lane: 1) Normal swine serum (negative control); 
2) ASFV-specific convalescent serum (positive control). Differences in coloration are 
due to actual band intensities; darker color is higher concentration of antibody bound to 
antigen (antigen concentration is constant).  
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Table 4: IFA Results 
 
Treatment 
Group: 
Swine No. 
 
Reactivity 
 
Control 
Group: 
Swine No. 
 
Reactivity 
ASFV- 
infected 
Vero cells 
Mock-
infected 
Vero cells 
ASFV-
infected 
Vero cells 
Mock-
infected 
Vero cells 
76 +++ - 77 - - 
78 - - 79 - - 
81 ++ - 80 - - 
82 +++ - 84 - - 
83 - - 85 - - 
89 +++ - 87 - - 
90 + - 88 - - 
91 ++++ - 93 - - 
92 + - 95 - - 
96 +++ - 99 - - 
ASFV 
convalescent 
serum 
++++ - Normal 
serum 
- - 
The number of ‘+’ signs represents the comparison between the intensity of a positive 
signal from the sera of the animals and that from the ASFV-specific convalescent serum 
(positive control). ‘++++’: signal as strong as positive control; ‘+’: weakest but positive 
signal; ‘-‘: No signal detected. 
 
 
3.4.4. Ad5-ASFV cocktail primed IFN-γ-secreting cells 
Low frequencies of antigen-specific IFN-γ responses were detected in a few animals by 
IFN-γ ELISPOT analysis of PBMCs collected one-week post-priming (Fig. 13A). 
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Specifically, a significant difference (p<0.05) between the mean response of the 
treatment group and negative control group animals was detected only for antigen 
A151R (Fig. 13A).  However, after boosting, strong recall IFN-γ+ responses were 
detected in a majority of animals for all the antigens (Fig. 13B).  The mean response of 
the treatment group was significantly higher than the control group for all antigens 
(p<0.05 for antigens B119L, B602L, EP402RΔPRR; and p<0.01 for antigens A151R, 
B438L, and K205R-A104R).  The IFN-γ ELISPOT data clearly showed that the 
homologous booster dose was able to sufficiently amplify the primary response to give 
strong recall responses against all antigens in a majority of the vaccinees (Fig. 13).  The 
high frequencies of antigen-specific IFN-γ+ cellular responses induced are promising in 
light of the results reported from other subunit vaccine studies. Notably, immunization 
with an ubiquitin tagged chimera of antigens p30, p54, and CD2v using DNA plasmids 
conferred protection against lethal challenge in some of the vaccinees [34].  In addition, 
in another study, by the same authors, immunizing animals with BacMams expressing 
the same antigen chimera (p30, p54, and CD2V) conferred partial protection upon a sub-
lethal challenge, and a direct correlation between protection and ASFV-specific IFN-γ+ 
response was observed [54]. Interestingly, in both studies the IFN-γ response against the 
extracellular domain of EP402R was negligible.  We have shown that the adenovirus-
vectored EP402RΔPRR induced strong antigen-specific IFN-γ+ responses in 70% of the 
vaccinees post-boost.  
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Figure 13. Antigen-specific IFN-γ response post-prime and post-boost. 
The frequency of antigen-specific IFN-γ-secreting cells in PBMCs collected post-prime 
and post-boost was evaluated by IFN-γ ELISPOT assays. Data for A) One week post-
prime; and B) three weeks post-boost is shown. The response is presented as IFN-γ Spot 
Forming Cells (SFC)/106 PBMCs. The mean response of the treatment group (T) was 
compared to the mean response of the control group (C) using an unpaired t-test with 
Welch’s correction. ** represents p<0.01, * represents p<0.05 and ‘ns’ stands for a non-
significant difference. 
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3.4.5. Ad5-ASFV cocktail was well tolerated 
Following inoculation of the Ad-ASFV cocktail, three swine in the treatment group were 
observed to be depressed and one had mild fever on the first day.  However, all the 
swine were normal on all subsequent days. After boosting, one pig in the treatment 
group was observed to be depressed and had fever that required treatment with 
Banamine.  All the swine in the negative control group were normal post-priming and 
post-boosting.  Overall, the Ad-ASFV cocktail was well tolerated with no adverse 
effects.  
The overall outcome is evidence that a vaccine formulated using a cocktail of 
replication-incompetent adenovirus expressing protective ASFV antigens is likely to be 
well tolerated by commercial swine at doses as high as 1011 IFU used in a homologous 
prime-boost immunization regimen.  This scenario is anticipated since effective ASFV 
subunit vaccines will likely require delivery of multiple antigens given that studies 
conducted so far have shown that a combination of one or a few antigens does not confer 
complete protection. 
3.5. Conclusions 
The African Swine Fever Virus (ASFV) continues to pose a high risk to the swine 
industry and it is still causing economic losses in endemic areas. Since there is no 
vaccine or treatment available yet, it is important to identify viral proteins that can elicit 
strong immune responses and therefore be considered viable candidates for subunit 
vaccine development. We have optimized an adenovirus-vector based ASFV antigen 
delivery system which allows for immunization of swine with multiple ASFV antigens 
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and the subsequent evaluation of their immunogenicity.  The robust antigen-specific 
IFN-γ+ responses induced by the adenovirus vector against all the antigens tested in this 
study as well as other ASFV antigens evaluated in our previous study make it a 
promising delivery platform for testing vaccine candidates for protection against ASFV 
[57]. An interesting observation is the relatively low B438L-specific humoral responses 
in contrast to the strong B438L-specific IFN-γ+ responses induced (Fig. 11 and Fig. 13).  
The inability of this antigen to induce strong antibody responses was corroborated by the 
fact that the ASFV-specific convalescent serum also had a comparatively low B438L-
specific titer (1:4,000).  Thus, even though B438L does not induce a high antibody 
response, it still is an attractive candidate for future efficacy studies based on its ability 
to induce strong IFN-γ+ cell responses.   This study also showed that an adenovirus-
based ASFV vaccine can be used successfully for homologous prime-boost vaccination.  
If this approach is shown to confer protection, it will cut costs incurred by use of a 
heterologous prime-boost immunization strategy.  Thus, these findings support use of the 
replication-incompetent adenovirus as a vector for the development of a commercial 
vaccine for protection of pigs against African swine fever virus.  The next logical step is 
to test whether these multiple ASFV antigens delivered in a cocktail format can confer 
protection in a challenge study.   
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CHAPTER IV                                                                                                                 
PRIMING CROSS-PROTECTIVE BOVINE VIRAL DIARRHEA VIRUS-SPECIFIC 
IMMUNITY USING LIVE-VECTORED MOSAIC ANTIGENS† 
4.1. Overview 
Bovine viral diarrhea virus (BVDV) plays a key role in bovine respiratory disease 
complex, which can lead to pneumonia, diarrhea and death of calves.  Current vaccines 
are not very effective due, in part, to immunosuppressive traits and failure to induce 
broad protection.  There are diverse BVDV strains and thus, current vaccines contain 
representative genotype 1 and 2 viruses (BVDV-1 & 2) to broaden coverage.  BVDV 
modified live virus (MLV) vaccines are superior to killed virus vaccines, but they are 
susceptible to neutralization and complement-mediated destruction triggered by 
passively acquired antibodies, thus limiting their efficacy.  We generated three novel 
mosaic polypeptide chimeras, designated NproE2123; NS231; and NS232, which incorporate 
protective determinants that are highly conserved among BVDV-1a, 1b, and BVDV-2 
genotypes.  In addition, strain-specific protective antigens from disparate BVDV strains 
were included to broaden coverage.  We confirmed that adenovirus constructs expressing 
these antigens were strongly recognized by monoclonal antibodies, polyclonal sera, and 
                                                 
† Reprinted from “Lokhandwala S, Fang X, Waghela SD, Bray J, Njongmeta LM, 
Herring A, et al. Priming Cross-Protective Bovine Viral Diarrhea Virus-Specific 
Immunity Using Live-Vectored Mosaic Antigens. PLoS ONE 2017;12(1): e0170425. 
doi:10.1371/journal.pone.0170425.” Copyright 2017 Shehnaz Lokhandwala, Xin Fang, 
Suryakant D. Waghela, Jocelyn Bray, Leo M. Njongmeta, Andy Herring, Karim W. 
Abdelsalam, Christopher Chase and Waithaka Mwangi. 
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IFN-γ-secreting T cells generated against diverse BVDV strains.  In a proof-of-concept 
efficacy study, the multi-antigen proto-type vaccine induced higher, but not significantly 
different, IFN-γ spot forming cells and T cell proliferation compared to a commercial 
MLV vaccine.  In regards to the humoral response, the prototype vaccine induced higher 
BVDV-1 specific neutralizing antibody titers, whereas the MLV vaccine induced higher 
BVDV-2 specific neutralizing antibody titers.  Following BVDV type 2a (1373) 
challenge, calves immunized with the proto-type or the MLV vaccine had lower clinical 
scores compared to naïve controls.  These results support the hypothesis that a broadly 
protective subunit vaccine can be generated using mosaic polypeptides that incorporate 
rationally selected and validated protective determinants from diverse BVDV strains.  
Furthermore, regarding biosafety of using a live vector in cattle, we also showed that 
recombinant human adenovirus-5 was cleared within one week following intradermal 
inoculation.   
4.2. Introduction 
Bovine viral diarrhea virus (BVDV), an infectious pathogen that is prevalent in cattle herds 
globally, is a key agent responsible for causing Bovine Respiratory Disease Complex 
(BRDC) [72].  Infection with BVDV can cause severe diarrhea, respiratory disease, 
immunosuppression, abortion, congenital malformations, and birth of persistently 
infected (PI) calves, which play a major role in virus transmission in herds [73].  
Immunosuppression caused by acute infection of unprotected calves allows secondary 
infections to establish and cause pneumonia or enteritis [74].  The secondary infections 
are responsible for high rates of morbidity and mortality, and it is estimated that the U.S. 
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livestock industry loses >$1billion annually due to BRDC [75, 76].   
  This virus is classified as a member of the genus Pestivirus within the family 
Flaviviridae [77].  Two BVDV genotypes (type 1 and 2) are recognized according to 
serological and genetic relatedness [78].  The BVDV isolates circulating in the world are 
heterogeneous: BVDV genotype 1 (BVDV-1) is subdivided into a minimum of 12 sub-
genotypes (BVDV1a, b, c.…l), whereas BVDV genotype 2 (BVDV-2) is classified into 
4 subtypes, 2a-2d [79, 80].  The BVDV can also be divided into cytopathic and non-
cytopathic biotypes (cpBVDV and ncpBVDV, respectively), based on their lytic effects 
on infected cells.  The BVDV isolates cause a wide range of disease manifestations, 
which include sub-clinical and persistent infections, fetal infections, and host 
immunosuppression [81].  Infected cattle begin to shed the virus into the environment 
for about ten continuous days starting as early as four days after subclinical infection, 
whereas PI animals shed the virus for their entire lifetime [82, 83].  The prevalence of PI 
animals in the United States is estimated at 1.7% of the cattle population, and these 
animals are considered to be the primary source of infection of susceptible animals [84].   
BVDV infection in cattle induces high titers of neutralizing antibodies that 
prevent reinfections especially with the same genotype/sub-genotype [85, 86].  Some 
studies have demonstrated prevention of clinical signs, but not viral shedding, in cattle 
upon challenge with BVDV-2 following immunization with BVDV-1 [87, 88].  Failure 
of vaccination has been attributed to infection with variant genotype(s) as well as 
development of antigenically distinct viruses in exposed animals [89, 90].  Individual PI 
cattle may also be a source of genetic variants that amplify following infection of 
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susceptible cattle [91, 92].  However, in the absence of neutralizing antibodies, 
mutations occur faster and more frequently in BVDV following infection of pregnant 
animals [93] .  Many of the virus genome mutations result in amino acid changes in E2 
glycoprotein, a key target of the neutralizing antibodies [92, 94].  The E2 glycoprotein is 
highly immunogenic and at least nine epitopes have been mapped within three antigenic 
domains [95-99]. One of these antigenic determinants is immunodominant in BVDV-1 
and there are three in BVDV-2 that induce neutralizing antibodies in animals [96].  
However, it is also reported that viremia can occur despite the presence of neutralizing 
antibodies in infected animals, and some animals can be protected against BVDV 
infection in the absence of E2-specific neutralizing antibodies, suggesting a role for 
neutralizing epitopes from other antigens and/or T cells in protection [100, 101].  
Clearance of BVDV infections has also been associated with strain-specific MHC-
restricted CD4+ and CD8+ T cell responses [86, 102].  Cell mediated response to 
infection is initially provided by E2 and NS2-3 antigen-specific helper CD4+ T cells 
[103-105].   
   Despite availability of vaccines, BVDV prevalence has not markedly reduced due, 
in part, to failure of the vaccines to confer broad protection [106, 107].  Currently, both 
killed and modified live virus (MLV) vaccines are commercially available [108].  The 
killed vaccine elicits primarily a humoral response with minimal cell mediated response, 
whereas MLV vaccines are better at inducing CD4+ and CD8+ T cells responses in 
addition to antibody responses [109].  Since the presence of BVDV-specific maternal 
antibodies interferes with efficacy of BVDV vaccines, especially MLV, immunization is 
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usually delayed until most of the maternal BVDV antibodies have waned [90, 110].  
However, BVDV-specific antibodies in each animal decline at different rates and thus, 
antibody titers in some calves fall below protective levels much earlier than expected, 
and in the presence of PI calves in the herd, there is a high risk of infection [111].  MLV 
vaccines are currently the most effective, but genotype-specific vaccines are not effective 
at conferring cross-protection and thus, protection against BVDV-1 and 2 requires a vaccine 
formulation that contains a representative of genotype type 1 and 2 viruses.  The MLV 
vaccines are not considered to be safe since the attenuated virus can revert to wild type 
virus, cause in-utero infections and mucosal disease, carry the risk of vaccine 
contamination with adventitious viruses, and are immunosuppressive [112, 113].  
Furthermore, MLV strains may cause ovarian lesions leading to infertility in cows [114].  
Both killed and MLV vaccine virus are traditionally grown in MDBK cells and recent 
findings show that calves fed colostrum from some dams vaccinated with killed BVDV 
vaccine formulated with adjuvant have a high incidence of a syndrome characterized by 
spontaneous bleeding, severe anemia with heavy bone marrow damage. There is evidence to 
show that the damage is due to maternal alloantibodies induced by the vaccines against 
bovine cell antigens, including MHC-I molecules, and the syndrome has been named bovine 
neonatal pancytopenia [115-117].   
Given the limitations of the current vaccines, there is a need to develop improved 
vaccines for safe, robust, and broad protection against diverse BVDV genotypes.  
Empirical selection and validation of protective immune targets that are conserved 
among diverse BVDV strains can be used to generate novel mosaic antigens for 
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development of a contemporary vaccine.  Similar strategies have been used to develop 
broadly protective vaccines to overcome a wide Influenza and HIV-1 genetic diversity 
[118-120].  The BVDV envelop (E2) and non-structural (NS2-3) antigens are 
immunodominant, and neutralizing antibody as well as T cell responses directed against 
these antigens can confer protection [121, 122].  Importantly, evaluation of BVDV-specific 
immune responses following resolution of acute infection has revealed that the E2, NS2-3, 
and N-terminal protease fragment (Npro) antigens contain CD4+ T-cell epitopes [102].  In 
addition, MHC DR-restricted T cell epitopes have been identified from conserved regions of 
E2 and NS2-3 [102, 104, 105, 122, 123].          
In this study, we generated a prototype vaccine composed of recombinant 
adenoviruses expressing three novel mosaic polypeptide chimeras, designated NproE2123; 
NS231; and NS232.  These antigens incorporated neutralizing epitopes, defined and predicted 
IFN-γ-inducing CD4+ T cell as well as cytotoxic T lymphocyte determinants that are highly 
conserved among BVDV-1a, b, and BVDV-2 genotypes [95, 96, 102, 122, 123].  In 
addition, strain-specific protective antigens from disparate BVDV strains whose genome 
sequences are available were included to broaden coverage.  We compared the 
immunogenicity and protective efficacy of this prototype adenovirus-vectored vaccine to a 
commercial MLV vaccine in calves.   
Adenovirus-vectored subunit vaccines are undergoing clinical trials in readiness for 
deployment [124, 125]; there is concern that persistence of the construct in host tissues may 
increase chances of generating replication-competent progenies if recombination with 
closely related viruses occurs.  Thus, we set out to determine replication-incompetent 
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recombinant human adenovirus-5 persistence at the skin injection site, the draining lymph 
node, and the spleen of calves following intradermal inoculation.   
4.3. Materials and Methods 
4.3.1. Design of genes encoding novel mosaic BVDV antigens 
Published reports on protective BVDV antibody and T-cell epitopes, sequenced 
genomes, and bioinformatics tools were used to design novel mosaic polypeptides, 
which incorporated consensus and strain-specific key antigenic determinants from 
BVDV-1 and 2 strains [95, 96, 102, 118, 119, 123, 126, 127].  Analysis of sequenced 
genomes showed that the Npro antigen is highly conserved, but the E2 and the NS2-3 
antigens have conserved and variable domains.  Amino acid sequences of the E2 
proteins from currently defined BVDV-1 or BVDV-2 genotypes were aligned and three 
novel mosaic E2 polypeptides, designated E21,2,3 (E21-3), each containing consensus E2 
determinants plus defined strain-specific neutralization epitopes were selected, and 
wherever there was no consensus at a specific amino acid position for the BVDV-1 
genotypes, amino acid from the BVDV-1b sequence was selected since this is the most 
prevalent sub-type in North America.  The E21-3 polypeptide sequence was fused in-
frame to the C-termini of the Npro polypeptide and the resultant chimeric polypeptide, 
designated NproE21-3, was used to generate a codon-optimized synthetic gene, designated 
npro-e21a-e21b-e22 (nproe21-3,), that also included flag tag sequence at the 3’ end.  Two 
additional mosaic polypeptides that incorporated consensus amino acids from diverse 
NS2-3 proteins, designated NS2-31 (from BVDV-1 genotypes) and NS2-32 (from BVDV-2 
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genotypes) were similarly designed and used to generate two synthetic gene sequences, 
designated ns2-31, and ns2-32, respectively, that also included the flag tag sequence at the 
3’ end.  Synthetic genes were codon-optimized, custom-made, cloned into pUC57 
vector, and sequence-verified by GenScript Inc., NJ, USA.  
4.3.2 Generation of recombinant adenovirus plasmid expression constructs  
The three synthetic genes (nproe21-3, ns2-31, and ns2-32) were subcloned into pDonR 
vector using the Gateway Technology (Life Technologies, NY, USA) to generate shuttle 
constructs.  Positive clones were identified by PCR screening of plasmid DNA in 
bacteria colonies using vector-specific forward primer and gene-specific reverse primer.  
Authentic entry constructs, designated pDonRNproE21-3, pDonRNS2-31, and pDonRNS2-
32, respectively were selected by DNA sequencing.  The selected constructs were used to 
transfer each gene into pAd adenovirus plasmid backbone by homologous recombination 
(Gateway Technology, Life Technologies, NY, USA) and recombinant constructs were 
identified by PCR screening as above.  Authentic recombinant plasmid constructs, 
designated pAdNproE21-3, pAdNS2-31, and pAdNS2-32, respectively were selected after 
DNA sequencing.    
4.3.3 Protein expression by plasmid constructs and generation of recombinant 
adenoviruses  
Protein expression was evaluated by immunocytometric analysis of human embryonic 
kidney (HEK)-293A cells grown in 12-well tissue culture plates and transfected with 1 
μg of the selected clones of the pAd DNA constructs, and then probed with anti-FLAG 
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mAb at 48 hr. post-transfection as previously described [128].  Five clones of each pAd 
construct were selected based on efficiency of protein expression as judged by the 
immunocytometric analysis, and 2 μg DNA of each construct was digested with Pac-I 
restriction enzyme.  The digested DNA was transfected into HEK-293A cells grown in 6-
well plates to generate recombinant adenoviruses that were designated AdNproE21-3, 
AdNS2-31, and AdNS2-32, respectively.  In addition, adenovirus expressing luciferase 
(AdLuc) was generated to serve as a negative control.  Protein expression by the 
AdNproE21-3, AdNS2-31, and AdNS2-32 adenoviruses was tested and validated by 
immunocytometric analysis of infected HEK-293A cells as above, whereas fluorescence 
was used to confirm luciferase expression.   
One clone of each recombinant adenovirus was selected for amplification based 
on protein expression.  The bulk viruses were tested for protein expression as above and 
following titer determination, replication competence of the recombinant adenoviruses 
was determined by immunocytometric analysis of HEK-293A (which supports 
adenovirus replication) and MDBK cells (susceptible to adenovirus infection, but do not 
support replication of replication-incompetent adenovirus) infected overnight with one 
MOI of each virus construct and then probed with an in-house generated rabbit anti-
adenovirus polyclonal IgG (1:500 dilution) followed by an alkaline-phosphatase-
conjugated anti-Rabbit IgG (1:1000) (Jackson ImmunoResearch, Cat #711-055-152) 
secondary antibody and Fast Red TR–Naphthol AS-MX as the substrate (Sigma, F4523) 
to evaluate infectivity. 
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4.3.4. Validation of the mosaic antigens using BVDV-specific antibodies and T cells  
Authenticity of the mosaic NproE21-3, NS2-31, and NS2-32 antigens was confirmed by 
immunocytometric analysis using E2-specific neutralizing monoclonal antibodies 
(mAbs) and polyclonal antibodies (pAbs) generated against diverse BVDV strains.  
Briefly, HEK-293A cells grown in 12-well plates were infected for 48 hr. with 
AdNproE21-3, AdNS2-31, AdNS2-32, or AdLuc and probed with anti-BVDV E2 mAbs 348 
and 26A (VMRD, Inc., Pullman, WA), goat anti-BVDV polyclonal sera (VMRD), and 
bovine anti-BVDV hyperimmune sera from steers immunized and challenged with 
multiple BVDV-1 and 2 strains [129].  Antigen authenticity was further confirmed by 
ELISA and western blot analysis using the above mentioned antibodies.   
The authenticity of the T-cell epitopes in the mosaic antigens was validated by 
proliferation assays using peripheral blood mononuclear cells (PBMCs) isolated from 
the BVDV-immunized steers [129].  Recombinant NproE21-3, NS2-31 and NS2-32 antigens 
were expressed by using recombinant baculoviruses in High Five cells (Thermo Fisher 
Scientific) generated using the Bac-to-Bac HBM TOPO Secreted Expression System 
(Thermo Fisher Scientific) as per manufacturer’s instructions and validated as above.  
These antigens were then affinity purified using Anti-FLAG M2 Affinity Gel (Sigma) 
and used at 5μg/ml to conduct 3H-Thymidine incorporation assays to quantify antigen-
specific T cell responses as previously described [128].  Heat killed BVDV-1b 
(CA0401186a) and BVDV-2 (A125) at 5μg/ml served as positive control antigens, 
whereas medium alone was the negative control.  The outcome of the cell proliferation 
was presented as counts per minute (cpm). 
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4.3.5. Immunization and challenge of calves 
Three groups (A, B, and C), of age-matched BVDV sero-negative and virus-free weaned 
Holstein calves (n=5) were identified as previously described [130] and used in this 
study as shown in Table 5.  Each calf in group A was inoculated subcutaneously (SQ) 
with a cocktail, designated AdBVDV, containing the AdNproE21-3, AdNS2-31, and AdNS2-
32 recombinant adenoviruses (5 x 1010 TCID50/construct) formulated in adjuvant E 
(BenchMark-Vaxliant).  Each calf in group B was similarly inoculated, but with a 
commercial MLV BVDV-1 and 2 vaccine (Bovi-Shield GoldTM, Zoetis Inc., Kalamazoo, 
MI), whereas each calf in group C was inoculated with the recombinant AdLuc.  
Seventy-nine days post-priming, the AdBVDV vaccinees and the negative controls 
received inoculation of the respective priming immunogen and dose as above.  One 
hundred and forty-nine days post-boosting, all the calves were challenged by intranasal 
administration of 2 x 106 TCID50 of BVDV-1373 using a human nasal atomizer. 
(http://www.teleflexarcatalog.com/anesthesia-respiratory/airway/categories/552). 
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Table 5: Calf Immunization Protocol 
Calves in the treatment group were inoculated subcutaneously with a cocktail of the 
AdNproE21-3, AdNS2-31, and AdNS2-32 recombinant adenoviruses (AdBVDV) expressing 
the BVDV antigens, whereas calves in the positive control group received a commercial 
BVDV MLV vaccine.  Calves in the negative control group were inoculated with the 
recombinant AdLuc.  The calves were boosted with the respective priming inoculum and 
dose. 
 
4.3.6. Cellular and humoral immune responses  
Two weeks post-priming and bi-weekly thereafter, PBMCs were isolated to evaluate and 
quantify proliferation of BVDV-specific T-cell responses as previously described [128].  
The PBMCs (2.5 x 105 cells/well) were cultured for 72 hr. at 37°C in triplicate wells of 
Calf ID Vaccine-Prime Vaccine-Boost 
4 AdBVDV AdBVDV 
12 AdBVDV AdBVDV 
13 AdBVDV AdBVDV 
22 AdBVDV AdBVDV 
23 AdBVDV AdBVDV 
   
3 BVDV MLV - 
14 BVDV MLV - 
19 BVDV MLV - 
24 BVDV MLV - 
27 BVDV MLV - 
   
10 Ad Luciferase Ad Luciferase 
18 Ad Luciferase Ad Luciferase 
25 Ad Luciferase Ad Luciferase 
28 Ad Luciferase Ad Luciferase 
29 Ad Luciferase Ad Luciferase 
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round-bottom 96-well plates in a total volume of 100 µl of complete RPMI-1640 
(cRPMI) medium containing 2.5 µg/ml defined BVDV CD4+ T cell epitope peptides 
[103].  The positive control was cRPMI medium containing 1.3 µg/ml concanavalin A 
(ConA), whereas medium alone served as a negative control.  Cells were labeled with 
0.25 µCi of 3H-thymidine for 6 hr., harvested using a semi-automatic cell harvester 
(Tomtec Life Sciences, Hamden, CT), and the incorporated 3H-thymidine was counted 
with a Micro-Beta liquid scintillation counter (Perkin Elmer, Waltham, MA).  The 
incorporation of 3H-thymidine by the proliferating PBMCs was presented as mean 
counts per minute (cpm) of triplicate wells (±1 SD).  
The PBMCs were also used to quantify BVDV-specific IFN--secreting cells by 
EliSpot assay as previously described [128].  The PBMCs (2.5 x 105 cells/well) were 
seeded into triplicate wells of MultiScreen-HA plates (EMD Millipore, Billerica, MA) in 
a final volume of 100 µl cRPMI medium containing 2.5 µg/ml BVDV CD4+ T cell 
epitope peptides.  The positive control was 1.3 µg/ml ConA, whereas medium alone 
served as a negative control.  The plates were incubated for 36 hr. at 37°C, washed, 
developed, and dried overnight as previously described [128].  Following quantification 
of the spots using an EliSpot reader (AID, Diagnostika GmbH, Germany), the mean 
number of spots in the negative control wells was subtracted from the mean number of 
spots in the cognate test wells to determine the mean number of BVDV-specific IFN--
secreting PBMCs and the results were presented as the mean number of spot-forming 
cells/106 PBMCs. Sera from blood collected two weeks post-boost and one week pre-
challenge were tested to determine BVDV-1 and BVDV-2 neutralizing antibody titers 
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using BVDV-1 (Singer, NADL, BJ, TGAC, CA0401186a) and BVDV-2 (890, 1373, 
A125) strains as previously described [131, 132].  Briefly, serum was heat inactivated at 
56°C for 30 min, and 25 µl of each serum was serially diluted (2-fold) in cell culture 
media without FBS in 96-well microtiter plates.  Stock BVDV virus containing 100 
TCID50/25µl was added to each test well.  In each test, a positive control serum was also 
included.  This serum/virus mixture was incubated for 1 hr., at 37°C, MDBK cells added, 
and the plates were incubated at 37°C in a humidified atmosphere of 5% CO2 for 72 hr.  
The cells were observed daily for CPE for cytopathic strains, whereas the non-cytopathic 
strains were detected by Immuno-peroxidase assay [133].  The results were presented as 
serum neutralization titers (SNT) [134]. 
4.3.7. Clinical parameters: viremia/WBC-platelet counts 
Calves were observed daily pre-immunization, post-immunization and post-challenge for 
coughing, nasal discharge and diarrhea.  Rectal  temperature post-challenge was taken 
daily  [135].  To determine virus titers post-challenge, blood was collected in vacutainer 
tubes (containing Sodium-EDTA) by jugular venipuncture, freeze-thawed to lyse cells, 
centrifuged and supernatants were used to determine BVDV titers as previously 
described [136].  Whole blood was used to determine CBC using Cell-Dyn 3700 
analyzer (Abbott Diagnostics, Lake Forest, IL 60045, USA) with veterinary package as 
bovines for automated counts (WBC, RBC, Hgb, MCV, PLT).  Thin blood smears were 
stained with Giemsa for differential white blood cell counts [137].  Platelet count 
verification, WBC count verification, RBC and WBC morphology was evaluated 
microscopically. 
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4.3.8. Persistence of recombinant adenovirus in cattle  
Presence of recombinant replication-incompetent adenovirus in cattle was tracked for 
three weeks post-inoculation by rescue of virus from tissue biopsies taken from the 
intradermal inoculation site.  Briefly, recombinant adenovirus (5 x 109 ifu) was 
inoculated (I.D) into nine marked sites on the neck of four steers.  One skin biopsy was 
taken from each site using a 4mm Biopsy Punch (American Screening, Shreveport, LA) 
on days 1-7, 14, and 21.  In addition, skin biopsies were concurrently collected from the 
flank region of each steer to serve as negative controls.  The steers were euthanized three 
weeks post-inoculation and samples of draining lymph node and spleen were collected.  
The fresh tissue samples collected were snap frozen in liquid nitrogen, ground and then 
resuspended in 1 ml DMEM (Invitrogen).  Following centrifugation, supernatants were 
filtered through 0.22 µm pore membrane, and 0.5 ml was added to one well of HEK-
293A cells (which supports adenovirus replication) grown in 12-well plates.  Supernatant 
from HEK-293A cells infected overnight with the recombinant adenovirus, and 
subjected to the same treatment as above was used as a positive control.  Three days 
post-infection, presence of adenovirus in the HEK-293A cells was evaluated by 
immunocytometric analysis using the rabbit anti-adenovirus polyclonal IgGs as above.  
Medium from the above HEK-293A cells was used to infect fresh cells, and seven days 
later the above process was repeated to confirm presence or absence of adenovirus.   
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4.3.9. Statistical analysis  
Analysis of Variance (ANOVA) followed by Tukey’s multiple comparison test was used 
to analyze the significance of the differences in BVDV-specific immune responses and 
disease indices between the treatments (groups A and B) and the negative control (group 
C) using GraphPad Prism 6 (Version 6.07, GraphPad Software, Inc. La Jolla, USA). 
Statistical significance was considered when P < 0.05. 
4.3.10. Ethics statement 
The study was conducted in accordance with the Public Health Service Policy on 
Humane Care and Use of Laboratory Animals as specified in the Health Research and 
Extension Act of 1985 (Public Law 99-158) or in accordance with the U.S Department 
of Agriculture policies as required by the Animal Welfare Act of 1966 (7.USC.2131 et 
seq) as amended in 1970, 1976, and 1985. The research protocol: AUP21010-65 was 
reviewed and approved by the Texas A&M University Institutional Animal Care and 
Use Committee to ensure compliance with PHS standards.  All animal care facilities are 
inspected twice per year.  The facilities and procedures for maintenance and care of 
animals are accredited by the American Association for Accreditation of Laboratory 
Animal Care.  Efforts were made to minimize suffering, and at the completion of the 
study, the calves were euthanized with an overdose of sodium pentobarbital.  This 
method is approved by the Panel on Euthanasia of the American Veterinary Medical 
Association 
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4.4. Results and Discussion 
4.4.1. Expression constructs encoding novel mosaic BVDV antigens 
Three synthetic genes (designated nproe21-3, ns2-31, and ns2-32) encoding novel BVDV 
mosaic antigens were designed as depicted in Fig. 14A.  The nproe21-3 chimeric gene 
encodes the N-terminal protease fragment (Npro), a consensus BVDV-1a envelope 
glycoprotein E2 mosaic gene (e21), a consensus BVDV-1b envelope glycoprotein E2 
mosaic gene (e22), and a consensus BVDV-2 envelope glycoprotein E2 mosaic gene 
(e23) fused in-frame to flag-tag.  The ns2-31 DNA fragment encodes a consensus BVDV-
1 Nonstructural protein 2-3 fused in-frame to flag-tag, whereas the ns2-32 DNA fragment 
encodes a consensus BVDV-2 Nonstructural protein 2-3 fused in-frame to flag-tag (Fig. 
14A).   
4.4.2 Expression of the mosaic BVDV antigens 
Immunocytometric analysis of HEK-293A cells transfected with the pAdNproE21-3, 
pAdNS2-31, or pAdNS2-32 constructs probed with anti-FLAG mAb confirmed that each 
construct expressed the encoded antigen (Fig. 14B).  Similarly, immunocytometric 
analysis of HEK-293A cells infected with the AdNproE21-3, AdNS2-31, or AdNS2-32 
recombinant adenoviruses probed with anti-FLAG mAb confirmed protein expression 
(Fig. 14C).  Analysis of replication competency confirmed that the AdNproE21-3, AdNS2-
31, and AdNS2-32 recombinant adenoviruses were replication-incompetent.     
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Figure 14. BVDV antigen expression constructs. 
A) Schematic diagram of expression cassettes encoding BVDV mosaic antigens:  i) 
Composition of the nproe21-3, chimeric gene: npro encodes Npro antigen; e21 encodes a 
mosaic BVDV-1a E2 envelope glycoprotein; e22 encodes a mosaic BVDV-1b E2 
envelope glycoprotein; whereas e23 encodes a mosaic BVDV-2 E2 envelope 
glycoprotein.  ii) ns2-31 encodes a mosaic BVDV-1 nonstructural protein 2-3. iii) ns2-33 
encodes a mosaic BVDV-2 nonstructural protein 2-3.  A gene (flag) encoding the FLAG 
tag was fused in-frame at the 3’ end of each chimeric gene for tracking protein expression 
and transcription was under the direction of the CMV promoter (CMVp).  The genes 
were cloned into adenovirus backbone plasmid vector and the resultant constructs were 
designated pAdNproE21-3, pAdNS2-31, and pAdNS2-32, respectively.    
B) Protein expression by recombinant plasmid constructs:  The plasmid DNA constructs 
encoding the three genes described in (A) above were transfected into HEK-293A cell 
monolayers and protein expression was evaluated by immunocytometric analysis using 
anti-FLAG M2-AP Conjugate as follows: HEK-293A cells monolayers were transfected 
with the following constructs: i) pAdNproE21-3; ii) pAdNS2-31; iii) pAdNS2-32; and iv) 
pAd vector (negative control). 
C) Protein expression by recombinant adenovirus constructs: HEK-293A cells 
monolayers were infected with the following recombinant adenovirus: i) AdNproE21-3; 
ii) AdNS2-31; iii) AdNS2-32; and iv) Ad-Luciferase.  Protein expression was evaluated 
by immunocytometric analysis as above. 
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4.4.3. Novel mosaic BVDV antigens are recognized by multiple BVDV-specific 
antibodies  
Authenticity of the mosaic antigens (NproE21-3, NS2-31, and NS2-32) expressed by the 
recombinant adenoviruses was confirmed by immunocytometric analysis of infected 
HEK-293A cells probed with BVDV neutralizing monoclonal antibodies and polyclonal 
sera raised against diverse BVDV strains (Fig. 15).  Anti-BVDV polyclonal sera from 
immunized goat and cattle reacted with all three recombinant antigens (NproE21-3, NS2-31, 
and NS2-32), whereas monoclonal antibodies 26A and 348, specific for the glycoprotein 
E2, reacted with NproE21-3 antigen only (Fig. 15A).  The outcome confirmed that 
neutralization epitopes in the mosaic NproE21-3 antigen were correctly expressed, and that 
the NS2-31 and NS2-32 mosaic antigens were specifically recognized by anti-BVDV 
polyclonal sera.  Thus, these antigens were expected to induce authentic BVDV-specific 
immune responses in cattle.  This expected outcome was consistent with previous 
demonstration that multicomponent mosaic antigens generated using this strategy elicit 
broadly protective pathogen-specific immune responses [126, 138, 139].      
 
 
 
 
 
 82 
 
 
Figure 15. Validation of B-cell epitopes in the mosaic BVDV antigens.  
Authenticity of the adenovirus-expressed novel BVDV mosaic antigens was confirmed 
by immunocytometric analysis using E2-specific neutralizing monoclonal antibodies 
26A and 348 (both neutralize BVDV-1 & 2); bovine anti-BVDV hyper-immune serum 
(generated by immunizing steers multiple times with BVDV-1 & 2 vaccines followed by 
boosting with killed diverse BVDV-1 & 2 strains and then challenged with wild type 
BVDV-1 & 2 strains (The sera have high BVDV-1 & 2 neutralizing titers [129]); and 
goat anti-BVDV polyclonal serum generated against multiple wild-type BVDV-1 & 2 
strains.  A) HEK-293A cells expressing NproE21-3; B) HEK-293A cells expressing 
NS2-31; C) HEK-293A cells expressing NS2-32; and D) HEK-293A cells expressing 
luciferase. 
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4.4.4. Novel mosaic BVDV antigens are recognized by BVDV-specific T lymphocytes 
The NproE21-3, NS2-31, and NS2-32 antigens stimulated robust proliferation of PBMCs 
from BVDV-immunized steers (Fig. 16).  The recall responses stimulated by the mosaic 
antigens were significantly (P<0.01) higher than the responses elicited by whole killed 
BVDV-1b or BVDV-2, suggesting that the mosaic antigens are likely to prime and 
amplify robust antigen-specific immune responses in vivo (Fig. 16).  These outcomes 
showed that the mosaic antigens were properly processed to generate peptides that were 
presented by MHC molecules to cognate BVDV-specific memory T-cells.  Previous 
studies have shown that mosaic antigens are processed by host APCs to generate 
relevant peptides for MHC presentation to elicit protective T-cell responses [140, 141]. 
 
 
 
Figure 16. Validation of mosaic antigens using BVDV-specific T-cells.  
Authenticity of T-cell epitopes in the mosaic BVDV antigens was validated by 
proliferation assay using PBMCs from a BVDV-1 & 2 hyper-immune steer [129].  The 
data shown is minus background counts from negative control (media alone) treatment.  
The asterisks denote a statistically significant difference (P<0.01) between the 
proliferation induced by the NproE21-3, NS2-31 and the NS2-32 antigens and both whole 
killed viruses BVDV-1b and BVDV-2. This outcome is representative of assays 
conducted using PBMCs from other BVDV immune steers.  
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4.4.5. Mosaic antigens elicited stronger BVDV-specific T-cell immune responses   
Immunogenicity and protective efficacy of the AdNproE21-3, AdNS2-31, and AdNS2-32 
recombinant adenovirus cocktail, designated AdBVDV, was evaluated in steers using a 
homologous prime-boost immunization regimen (Table 5 and Fig. 17).   
 
One week after the AdBVDV vaccinees were boosted, the cocktail elicited 
higher, but not significantly different, BVDV-specific IFN-γ-secreting PBMCs as well as 
BVDV-specific PBMC proliferation compared to the vaccinees that received the 
commercial MLV BVDV vaccine (Fig. 18A & C).  The mean responses mounted by the 
AdBVDV vaccinees, but not the MLV vaccinees, were significantly higher (P<0.05) 
than the negative controls.  Before challenge (five months after the AdBVDV vaccinees 
were boosted) the AdBVDV-induced mean IFN-γ+ response had increased and was 
Figure 17. Immunization timeline. 
On day -228 pre-challenge, cattle in the treatment group were vaccinated with a cocktail 
of the recombinant adenoviruses expressing mosaic BVDV antigens (AdBVDV), 
whereas positive control cattle received a commercial MLV BVDV vaccine.  Negative 
control cattle were inoculated with the recombinant Ad-luciferase.  On day -149 pre-
challenge, the cattle were boosted with the respective priming inoculum and dose (Table 
I).  On day 0, all the cattle were challenged by intranasal delivery of a BVDV-1373 using 
an atomizer.  Blood samples were collected on selected days (0, 3, 6, 10, 12, 13 and 15), 
whereas clinical observations and rectal temperatures were monitored and recorded daily 
from days 1-15 post-challenge.  
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significant (P<0.05) compared to the negative controls, whereas the mean IFN-γ+ 
response in the MLV vaccinees had already declined (Fig. 18B).  This decrease in the 
mean IFN-γ response in the MLV BVDV vaccine treatment group one week before 
challenge, might have had an impact on clearance of the challenge virus. 
Figure 18. Mosaic BVDV vaccine elicited strong T-cell responses. 
Immunization of cattle with adenovirus-vectored mosaic BVDV vaccine primed and 
expanded BVDV-specific T-cells.  A commercial MLV BVDV vaccine served as a 
positive control, whereas Ad-Luciferase served as a negative control.  EliSpot assays 
were used to evaluate BVDV-specific IFN-γ-secreting PBMC responses against defined 
BVDV T-cell epitopes and data is shown for A) One-week post-boost; and B) Day 0 of 
challenge.  Outcome is presented as IFN-γ+ SFC/106 PBMC.  Cell proliferation assays 
were used to evaluate BVDV-specific PBMC responses and data is shown for C) One-
week post-boost; and D) one-week pre-challenge.  Proliferation of the PBMCs in 
response to defined BVDV T-cell epitopes is presented as the means ± standard 
deviations of 3H-thymidine incorporation by the cells from triplicate wells.  In both 
assays, medium alone served as the negative control and the data shown is minus media 
background counts.  The group mean is represented by a bar. Asterisks denote 
statistically significant differences, *P<0.05. 
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The mean BVDV-specific PBMC proliferation increased in both the vaccinated 
groups, but only the AdBVDV- and not the MLV-induced response was significantly 
different (P<0.05) from the AdLuc control group (Fig. 18D).  The increase in mean IFN-
γ response and PBMC proliferation in the AdBVDV treatment group at five months 
post-boost, were not significantly different from the responses recorded at one week 
post-boost (Fig. 18).   
4.4.6. Mosaic antigens elicited cross-neutralizing BVDV-specific antibody responses   
Following boosting of the AdBVDV vaccinees, the levels of BVDV neutralizing serum 
antibodies against five BVDV-1 strains and three BVDV-2 strains were evaluated at one-
week post-boost and one-week pre-challenge (Fig. 19 and 20).  The adenovirus cocktail 
induced higher mean neutralizing antibody titers post-boost against all BVDV-1 strains 
compared to the responses stimulated by the commercial MLV BVDV vaccine and the 
AdLuc controls.  The difference between the mean titers however, was significant only 
for the non-cytopathic BVDV-1b BJ (P<0.05) and BVDV CA0401186a strains 
(AdBVDV vs MLV, P<0.05; AdBVDV vs AdLuc, P<0.01) (Fig. 19A).  Furthermore, the 
mean AdBVDV titers increased up to five months post-boost (one-week pre-challenge) 
against 4 of 5 BVDV-1 strains whereas, the mean MLV titers either remained the same 
or declined.  These mean AdBVDV titers remained significantly higher (P<0.05) than 
the MLV vaccinees and the AdLuc controls for the BJ strain, and only the AdLuc 
controls for the cytopathic BVDV-1a NADL strain.  Interestingly, for all three BVDV-2 
strains, the mean titers of the MLV vaccinees were higher (in contrast to BVDV-1) than 
the AdBVDV vaccinees post-boost (Fig. 20A).  These mean MLV titers were 
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significantly higher (P<0.05) than the AdBVDV vaccinees only for strain A125 and 
significantly higher than the AdLuc controls for all three strains (P<0.05 for strain 890; 
P<0.01 for strains 1373 and A125).  The mean BVDV-2-specific titers in both the 
AdBVDV vaccinees as well as the MLV vaccinees increased before challenge.  Thus 
overall, the AdBVDV vaccine cocktail was able to induce high titers against all 8 BVDV 
strains tested in 3 out of 5 calves, whereas the MLV vaccine was able to induce high 
titers against only BVDV-2 strains.  It is also noteworthy that the 3 AdBVDV vaccinees 
had substantially higher neutralizing titers (1:1,024 - 1: 2,048) when compared to the 
MLV vaccinees (1:32 - 1:256) against the NADL strain which is a component of the 
commercial MLV vaccine they received. 
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Figure 19. Mosaic BVDV vaccine induced BVDV-1 specific neutralizing antibodies. 
Serum neutralization assays were used to evaluate BVDV-1-specific neutralization titers 
at A) One-week post-boost; and B) one-week pre-challenge against five BVDV type 1 
strains.  Mean group titers are represented by the bars.  Statistically significant 
differences between the groups are denoted by asterisks. *P<0.05; **P<0.01. 
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Figure 20.  Mosaic BVDV vaccine induced BVDV-2 specific neutralizing antibodies. 
BVDV-2-specific neutralization titers against three BVDV type 2 strains were evaluated 
at A) two weeks post-boost; and B) one week pre-challenge.  Mean group titers are 
represented by the bars. Statistically significant differences between the groups are 
denoted by asterisks *P<0.05; **P<0.01.     
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4.4.7. Clinical observations, hematology and viremia 
Following the BVDV challenge, there were no obvious differences in clinical score 
among all the animals, however, characteristic biphasic pyrexia was observed for the 
negative controls but not for the AdBVDV or the MLV vaccinees (Fig. 21A).  On day 5 
post-challenge, the transient rise in mean rectal temperatures of the negative controls 
was significantly higher (P<0.001) than the MLV vaccinees but not the AdBVDV 
vaccinees. The mean rectal temperatures for the negative controls rose again on day 9, 
peaked at day 10 and normalized by day 11 post-challenge.  The mean temperatures of 
the controls were significantly higher than AdBVDV vaccinees on days 9 (P<0.05) and 
10 (P<0.001) post challenge, and the MLV vaccinees on days 8 (P<0.01), 9 (P<0.001) 
and 10 (P<0.001) post-challenge (Fig. 21A).  The negative control animals also 
exhibited transient leucopenia from days 6 to 9 post-challenge with a 32-40% reduction 
against baseline (day 0) white blood cell (WBC) counts.  This reduction of WBCs in the 
negative controls was significant compared to the AdBVDV vaccinees on days 6 
(P<0.05) and 9 (P<0.01) post-challenge, and the MLV vaccinees on days 6 (P<0.01), 7 
(P<0.01) and 9 (P<0.001) post-challenge (Fig. 21B).  There was no significant difference 
in platelet counts among the treatment groups post-challenge.  On days 7 and 10 post-
challenge, no virus was detected in all the AdBVDV vaccinees (Table 6).  However, 
BVD virus was detected from the blood of one of the steers that received the commercial 
MLV BVDV vaccine on day 7 but not on day 10 post-challenge, and from the blood of 
all the negative controls up to day 15 post-challenge (Table 6).   
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Figure 21. Clinical manifestations post-challenge.      
A) Mean rectal temperature fluctuation; and B) Mean change ratios of white blood cell 
counts in the vaccinated and negative control groups post-challenge.  Asterisks denote 
statistically significant differences as compared to the negative controls. *P<0.05; 
**P<0.01 and ***P<0.001.    
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Table 6: Virus Isolation from Calves on Day 7 and Day 10 Post-Challenge 
Viremia in blood samples taken on days 7 and 10 post-challenge was evaluated by 
immunocytometric analysis of MBDK cells probed with goat anti-BVDV polyclonal 
serum. The dilution at which the samples were positive is specified. Sample dilutions 
further than 10-3 were not tested.  
 
 
4.4.8. Recombinant adenovirus inoculated intradermally is short lived   
Persistence of recombinant replication-incompetent adenovirus at the intradermal 
inoculation site, the draining lymph node, and the spleen was monitored by HEK-293A 
cell-dependent virus rescue followed by immunocytometric analysis using adenovirus-
specific polyclonal antibody.  One-day post-inoculation, adenovirus was readily 
Cattle ID Vaccine Viremia 
  Day 7 post-challenge Day 10 post-challenge 
4 AdBVDV - - 
12 AdBVDV - - 
13 AdBVDV - - 
22 AdBVDV - - 
23 AdBVDV - - 
    
3 BVDV MLV - - 
14 BVDV MLV - - 
19 BVDV MLV - - 
24 BVDV MLV - - 
27 BVDV MLV + (10-2) - 
    
10 Ad Luciferase + (10-3) + (10-3) 
18 Ad Luciferase + (10-3) + (10-3) 
25 Ad Luciferase + (10-3) + (10-3) 
28 Ad Luciferase + (10-3) + (10-3) 
29 Ad Luciferase + (10-3) + (10-3) 
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recovered from the skin biopsies collected from the inoculation sites, but not from the 
control sites (Fig. 22B and C).  Virus recovery decreased drastically by day two post-
inoculation and very few viral particles were recovered at day three (Fig. 22 E and H).  
No virus was recoverable from all skin biopsies collected on days 4-7 post-inoculation 
(Fig. 22 K).  Skin biopsies collected on days 14 and 21, and draining lymph node and 
spleen samples collected on day 21 were all negative (Fig. 22 N and O).  The medium 
from the HEK-293A cells used to test the samples collected on days 4-7, 14, and 21, was 
negative after a second round of screening.  These outcomes are consistent with previous 
findings in rodents [142].  Given that ABSL2 biocontainment is required for in vivo 
studies using the replication-incompetent adenovirus, data from this pilot study suggest 
that it is safe to downgrade biocontainment after seven days post-inoculation.  However, 
the fate of the vector genome in cattle and environmental risk assessment will need to be 
determined.             
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Figure 22. Persistence of replication-incompetent adenovirus in cattle. 
Viable recombinant adenovirus inoculated intradermally is only recoverable within three 
days.  Presence of adenovirus rescued from tissue samples of four steers at defined time 
points was tracked by immunocytometric analysis of HEK-293A cells.  Representative 
data from one steer is shown:  A, D, G, J, and M are positive controls at 24 hr., 48 hr., 72 
hr., day 7, and day 21, respectively.  B, E, H, and K, are skin biopsies taken from the 
inoculation sites on the neck of the steers at 24 hr., 48 hr., 72 hr., and day 7, respectively, 
whereas C, F, I, and L, are cognate control skin biopsies taken concurrently from the 
flank.  N and O are draining lymph node and spleen samples, respectively, collected three 
weeks post-inoculation.    
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4.5. Conclusions  
The purpose of this study was to develop an efficacious BVDV vaccine which a) 
overcomes the several disadvantages associated with the MLV vaccine mentioned 
previously and b) provides broad protection against multiple BVDV genotypes.  To this 
end, we designed mosaic polypeptide consensus sequences of highly immunogenic 
BVDV antigens such as Npro, E2 glycoprotein and the Nonstructural protein 2-3 based on 
multiple genotypes.  We selected live replication deficient adenovirus as a vector for 
delivery of these antigens to prime strong humoral as well as cell mediated immune 
responses. Polyclonal anti-BVDV sera and monoclonal anti-E2 antibodies strongly 
recognized these mosaic antigens by immunocytometric analysis.  Furthermore, PBMCs 
from BVDV immune steers proliferated strongly upon stimulation by these mosaic 
antigens.  The above outcomes confirmed the authenticity of both B-cell and T-cell 
epitopes in all the mosaic antigens. 
Calves immunized with a cocktail of recombinant adenoviruses expressing these 
antigens had stronger IFN-γ+ and proliferation responses to defined BVDV CD4+ T-cell 
epitopes as compared to calves vaccinated with the commercial BVDV MLV vaccine.  In 
addition, the AdBVDV vaccinees had higher serum neutralizing titers against BVDV-1 
than the MLV vaccinees.  In case of BVDV-2, the MLV vaccinees had higher mean titers 
one-week post-boost, but the AdBVDV mean titers increased over time and before 
challenge were equivalent or higher than the MLV vaccinees for 2 of 3 strains tested.  
Importantly, both BVDV-1 and BVDV-2 neutralizing antibody titers along with the 
cellular IFN-γ+ and proliferation immune responses considerably increased for up to five 
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months post-boost (one week before challenge) in most AdBVDV vaccinees, whereas 
only the BVDV-2 specific titers and the mean proliferation responses amplified in the 
MLV vaccinees.  Upon challenge with a BVDV-2a strain, both vaccinated groups 
showed no clinical signs of infection.  The negative controls, however, had a mild fever 
on day 5 post-challenge followed by more severe pyrexia on day 10 post-challenge.  
Moreover, the negative controls also had significantly lower WBC counts than both 
vaccinated groups.  Rapid clearance of virus is an attractive trait in a BVDV vaccine.  
All the AdBVDV vaccinees had cleared the virus as early as 7 days post-challenge, 
whereas one MLV vaccinee was still viremic on day 7 but not on day 10 post-challenge.  
All negative controls remained viremic up to day 15 post-challenge.  With regards to the 
safety concern and ABSL2 biocontainment when using human Ad5 as a delivery vector, 
we showed that the replication-incompetent Ad5 virus is cleared from the inoculation 
site within four days post-injection and is not recovered from either the draining lymph 
node or the spleen after 21 days post-inoculation.  
Overall, data from this study showed that the AdBVDV prototype vaccine is 
more immunogenic and offers better cross-protection than the commercial MLV vaccine 
in terms of cell mediated and neutralizing antibody responses.  As far as protective 
efficacy is concerned, the AdBVDV vaccine performed at par if not better than the MLV 
vaccine upon challenge by BVDV-2a strain. Notably, this study is the first to report 
heterologous protection using subunit BVDV vaccines.  Future studies with larger 
animal sample sizes, different vaccine doses and challenge with diverse BVDV strains 
need to be conducted to further optimize the AdBVDV prototype vaccine.   
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The protective potential of the BVDV E2 antigen has been successfully 
demonstrated in the past using various delivery platforms like live-vectors, DNA 
immunizations or as a recombinant protein produced in different expression systems [9, 
143-145]. Current efforts are now focused on enhancing this potential using modern 
adjuvants and antigen carriers such as PRR activators, APC targeting molecules and 
silica nanoparticles [146-149]. This study highlights the cross-protective potential of the 
novel mosaic polypeptides and is the first to report heterologous protection using subunit 
BVDV vaccines. Thus, future studies using these mosaic polypeptide sequences in 
conjunction with modern immune-response enhancing strategies may lead to a very 
effective and cross-protective BVDV vaccine. 
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CHAPTER V                                                                                                     
SUMMARY 
 
The goal of the work described in this dissertation was to rationally develop prototype 
vaccines against two pathogens, ASFV and BVDV. The major conclusions drawn from 
the in-vivo studies reported here are as follows:  
5.1. African Swine Fever Virus 
- The multivalent Ad-ASFV cocktails induced strong antibody responses and IFN-
γ+ responses against each antigen in the cocktail. 
- The Ad-ASFV cocktail was able to prime CTLs (evaluated only in the first 
study) capable of recognizing and killing target cells presenting each antigen in 
the cocktail. This is the first demonstration of induction of ASFV antigen-
specific CTL responses in commercial pigs using an Ad-ASFV multivalent 
cocktail. 
- Both Ad-ASFV cocktails were well tolerated with no adverse effects.  
- The protective potential of the responses induced need to be evaluated in efficacy 
studies 
5.2. Bovine Viral Diarrhea Virus 
- The AdBVDV prototype vaccine was more immunogenic and cross-protective 
than the commercial MLV vaccine 
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- This is the first demonstration of heterologous protection in case of BVDV using 
a subunit vaccine. 
- Further studies involving large sample sizes, vaccine dose optimization and 
challenge with various BVDV strains are required before the possible 
commercialization of this prototype vaccine.  
Overall, these in-vivo studies demonstrate that using live-adenovirus vector to 
deliver rationally selected/designed antigens can be a promising and safe approach for 
developing veterinary vaccines. 
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APPENDIX 
 
Supplementary Data 
 
Figure A1.  Validation of affinity purified ASFV antigens. 
Recombinant ASFV antigens were affinity purified using anti-FLAG agarose and their 
authenticity was confirmed by western blotting using ASF-specific convalescent 
serum. 
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Figure A2.  Adenovirus vector-specific serum IgG profiles post-priming. 
Adenovirus vector-specific IgG response was monitored bi-weekly post-prime up to 
week 10 by ELISA (sera were diluted at 1:1000). Color scheme used, T1: Blue; T2: 
Maroon; T3: Green; and T4: Gray.  The absorbance values at 450 nm across weeks 2, 
4 ,6, 8 & 10 post-prime for each animal are depicted using a color gradient where the 
lightest shade (first bar) represents week 2 and the darkest shade (last bar) represents 
week 10. Error bars show standard deviation among triplicate absorbance values. The 
profile is similar to that observed for ASFV antigen-specific antibodies, specifically 
the decline seen at week 10. 
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Figure A3. Recall antigen-specific serum IgG profiles post-boost. 
Antigen-specific IgG responses were monitored weekly post-boost up to week 4 by 
ELISA (sera were diluted at 1:1000). The color scheme for the treatment groups is 
same as shown in Figure 3. The absorbance values at 450 nm across weeks 1, 2, 3 & 4 
post-boost for each animal are depicted using a color gradient where the lightest shade 
(first bar) represents week 1 and the darkest shade (last bar) represents week 4. The 
absorbance for some animals exceeded the upper limit of detection (greater than 3.0) 
and is shown in the profiles at a maximum value of 3.0. Error bars show standard 
deviation among triplicate absorbance values. 
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Figure A4.  Western blot of lysates from mock-infected Vero cells. 
Blots were probed with individual serum for each animal in the study to assess 
background reactivity to host cell antigens. 
 
 
